BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. [PMID: 11583749 DOI: 10.1016/s0140-6736(01)06102-5] [Cited by in Crossref: 4536] [Cited by in F6Publishing: 1298] [Article Influence: 216.0] [Reference Citation Analysis]
Number Citing Articles
1 Nagao Y, Sata M. Dental problems delaying the initiation of interferon therapy for HCV-infected patients. Virol J 2010;7:192. [PMID: 20712912 DOI: 10.1186/1743-422X-7-192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Guardigni V, Badia L, Conti M, Rinaldi M, Mancini R, Viale P, Verucchi G. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. World J Hepatol 2017; 9(34): 1270-1277 [PMID: 29290908 DOI: 10.4254/wjh.v9.i34.1270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 [PMID: 23919217 DOI: 10.4292/wjgpt.v4.i3.54] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
4 Balk JM, Haenen GR, Koc ÖM, Peters R, Bast A, van der Vijgh WJ, Koek GH. Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial. Pharmgenomics Pers Med 2015;8:137-44. [PMID: 26445557 DOI: 10.2147/PGPM.S82782] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004;19:357-65. [PMID: 15061745 DOI: 10.1111/j.1525-1497.2004.30613.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 3.5] [Reference Citation Analysis]
6 Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81:8211-8224. [PMID: 17522222 DOI: 10.1128/jvi.00487-07] [Cited by in Crossref: 92] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
7 Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. World J Hepatol 2018; 10(1): 88-94 [PMID: 29399282 DOI: 10.4254/wjh.v10.i1.88] [Reference Citation Analysis]
8 Lashin AH, Shaheen YA, Metwally MA, El-Feky HM, Hegab MF, Abbas SM. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin. Indian J Gastroenterol 2013;32:316-23. [PMID: 23715642 DOI: 10.1007/s12664-013-0336-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Pang KR, Wu JJ, Huang DB, Tyring SK, Baron S. Biological and clinical basis for molecular studies of interferons. Methods Mol Med 2005;116:1-23. [PMID: 16007741 DOI: 10.1385/1-59259-939-7:001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 0.1] [Reference Citation Analysis]
10 Livingston SE, Townshend-Bulson LJ, Bruden DJ, Homan CE, Gove JE, Plotnik JN, Simons BC, Spradling PR, McMahon BJ. Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. Int J Circumpolar Health 2016;75:30696. [PMID: 27029671 DOI: 10.3402/ijch.v75.30696] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W 4th, Cheng G. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 2014;58:2638-46. [PMID: 24550344 DOI: 10.1128/AAC.01780-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
12 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
13 Jardim ACG, Shimizu JF, Rahal P, Harris M. Plant-derived antivirals against hepatitis c virus infection. Virol J 2018;15:34. [PMID: 29439720 DOI: 10.1186/s12985-018-0945-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
14 Lee I, Localio R, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, Amorosa VK, Lo Re V 3rd. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant 2011;30:1266-74. [PMID: 21764330 DOI: 10.1016/j.healun.2011.06.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
15 Gao DY, Zhang XX, Hou G, Jin GD, Deng Q, Kong XF, Zhang DH, Ling Y, Yu DM, Gong QM, Zhan Q, Yao BL, Lu ZM. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin. J Clin Microbiol 2008;46:3746-51. [PMID: 18832124 DOI: 10.1128/JCM.00612-08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
16 Zhang R, Shao C, Huo N, Li M, Xu X. Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. Gut Liver 2016;10:446-55. [PMID: 26470765 DOI: 10.5009/gnl15162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596-605. [PMID: 22438096 DOI: 10.1007/s00535-012-0531-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
18 Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas MR, Mousavi T. Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis. Exp Ther Med 2018;16:971-8. [PMID: 30116347 DOI: 10.3892/etm.2018.6255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Hepatol Int. 2015;9:76-83. [PMID: 25788382 DOI: 10.1007/s12072-014-9589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010;2:30ra32. [PMID: 20445200 DOI: 10.1126/scitranslmed.3000544] [Cited by in Crossref: 269] [Cited by in F6Publishing: 251] [Article Influence: 22.4] [Reference Citation Analysis]
21 Brown JA, Thorpe IF. Dual Allosteric Inhibitors Jointly Modulate Protein Structure and Dynamics in the Hepatitis C Virus Polymerase. Biochemistry 2015;54:4131-41. [PMID: 26066778 DOI: 10.1021/acs.biochem.5b00411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
22 Rowan PJ, Bhulani N. Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. World J Hepatol 2015; 7(19): 2209-2213 [PMID: 26380046 DOI: 10.4254/wjh.v7.i19.2209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
23 Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol 2008;8:644-54. [PMID: 18654572 DOI: 10.1038/nri2377] [Cited by in Crossref: 94] [Cited by in F6Publishing: 92] [Article Influence: 6.7] [Reference Citation Analysis]
24 Sherman M, Cohen L, Cooper MA, Elkashab M, Feinman V, Fletcher D, Girgrah N, Heathcote J, Levstik M, McNaull WB, Wong D, Wong F, Yim C. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-85. [PMID: 16858501 DOI: 10.1155/2006/497059] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
25 Kim S, Jin B, Choi SH, Han KH, Ahn SH. Casein kinase II inhibitor enhances production of infectious genotype 1a hepatitis C virus (H77S). PLoS One 2014;9:e113938. [PMID: 25464014 DOI: 10.1371/journal.pone.0113938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
26 Cheney IW, Lai VC, Zhong W, Brodhag T, Dempsey S, Lim C, Hong Z, Lau JY, Tam RC. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol 2002;76:11148-54. [PMID: 12368359 DOI: 10.1128/jvi.76.21.11148-11154.2002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
27 Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS; Canadian Pegasys Study Group. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55:1631-8. [PMID: 16709661 DOI: 10.1136/gut.2005.083113] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 3.8] [Reference Citation Analysis]
28 Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, Okuzaki D, Maehara Y, Koike K, Matsuura Y. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J Virol. 2012;86:7918-7933. [PMID: 22593164 DOI: 10.1128/jvi.00567-12] [Cited by in Crossref: 89] [Cited by in F6Publishing: 42] [Article Influence: 8.9] [Reference Citation Analysis]
29 Poat B, Hazari S, Chandra PK, Gunduz F, Alvarez X, Balart LA, Garry RF, Dash S. Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virol J 2010;7:265. [PMID: 20939906 DOI: 10.1186/1743-422X-7-265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sidhu SS, Malhi NS, Goyal O, Singh R, Dutta U, Grover R, Sidhu JS, Nanda V, Saluja H, Bansal A, Singh G, Sehgal A, Kishore H, Sidhu S. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study. Hepatol Int 2017;11:277-85. [PMID: 28361300 DOI: 10.1007/s12072-017-9794-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Vliegen I, Paeshuyse J, De Burghgraeve T, Lehman LS, Paulson M, Shih IH, Mabery E, Boddeker N, De Clercq E, Reiser H, Oare D, Lee WA, Zhong W, Bondy S, Pürstinger G, Neyts J. Substituted imidazopyridines as potent inhibitors of HCV replication. J Hepatol 2009;50:999-1009. [PMID: 19303654 DOI: 10.1016/j.jhep.2008.12.028] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
32 Yee LJ, Im K, Borg B, Yang H, Liang TJ; Virahep-C Study. Interleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infection. Genes Immun 2009;10:365-72. [PMID: 19387461 DOI: 10.1038/gene.2009.26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
33 Sood A, Midha V, Goyal O. Treatment of chronic hepatitis C genotype 1 early responders with 36 week pegylated interferon and ribavirin therapy. Annals of Hepatology 2014;13:503-9. [DOI: 10.1016/s1665-2681(19)31249-9] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Zoller H, Jenal A, Staettermayer AF, Schroecksnadel S, Ferenci P, Fuchs D. Tryptophan Breakdown in Patients with HCV Infection is Influenced by IL28B Polymorphism. Pharmaceuticals (Basel) 2015;8:337-50. [PMID: 26096654 DOI: 10.3390/ph8020337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Doucette KE, Robson V, Shafran S, Kunimoto D. Improving access to care by allowing self-referral to a hepatitis C clinic. Can J Gastroenterol 2009;23:421-4. [PMID: 19543572 DOI: 10.1155/2009/216903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
36 Wen Y, Zheng YX, Tan de M. A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. Hepat Mon 2015;15:e27181. [PMID: 26045707 DOI: 10.5812/hepatmon.15(5)2015.27181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
37 Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, Cheever LW, Cargill VA. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40 Suppl 5:S276-85. [PMID: 15768335 DOI: 10.1086/427441] [Cited by in Crossref: 145] [Cited by in F6Publishing: 147] [Article Influence: 9.1] [Reference Citation Analysis]
38 Ray U, Roy CL, Kumar A, Mani P, Joseph AP, Sudha G, Sarkar DP, Srinivasan N, Das S. Inhibition of the interaction between NS3 protease and HCV IRES with a small peptide: a novel therapeutic strategy. Mol Ther 2013;21:57-67. [PMID: 22910295 DOI: 10.1038/mt.2012.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
39 Ali Ashfaq U, Ansar M, Sarwar MT, Javed T, Rehman S, Riazuddin S. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA. Virol J. 2011;8:112. [PMID: 21388559 DOI: 10.1186/1743-422x-8-112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 Maieron A, Metz-Gercek S, Hackl F, Ziachehabi A, Fuchsteiner H, Luger C, Mittermayer H, Schöfl R. Antiviral treatment of chronic hepatitis C in clinical routine. Wien Klin Wochenschr. 2010;122:237-242. [PMID: 20503023 DOI: 10.1007/s00508-010-1364-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Simeon RL, Chen Z. A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication. PLoS One 2013;8:e84022. [PMID: 24391867 DOI: 10.1371/journal.pone.0084022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
42 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2373-2376 [DOI: 10.11569/wcjd.v12.i10.2373] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Birerdinc A, Afendy A, Stepanova M, Younossi I, Baranova A, Younossi ZM. Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C). Brain Behav 2012;2:525-31. [PMID: 23139898 DOI: 10.1002/brb3.72] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
44 Shi ST, Herlihy KJ, Graham JP, Nonomiya J, Rahavendran SV, Skor H, Irvine R, Binford S, Tatlock J, Li H, Gonzalez J, Linton A, Patick AK, Lewis C. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009;53:2544-52. [PMID: 19307358 DOI: 10.1128/AAC.01599-08] [Cited by in Crossref: 65] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
45 Lin CC, Luu K, Lourenco D, Yeh LT. Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys. Antimicrob Agents Chemother 2003;47:2458-63. [PMID: 12878505 DOI: 10.1128/AAC.47.8.2458-2463.2003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
46 Shehab H, Elbaz T, Deraz D, Hafez A, Elattar I. The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C. J Interferon Cytokine Res 2014;34:727-33. [PMID: 24730368 DOI: 10.1089/jir.2013.0127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
47 Nyanguile O, Pauwels F, Van den Broeck W, Boutton CW, Quirynen L, Ivens T, van der Helm L, Vandercruyssen G, Mostmans W, Delouvroy F, Dehertogh P, Cummings MD, Bonfanti JF, Simmen KA, Raboisson P. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors. Antimicrob Agents Chemother 2008;52:4420-31. [PMID: 18852280 DOI: 10.1128/AAC.00669-08] [Cited by in Crossref: 33] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
48 Zanini B, Benini F, Pigozzi MG, Furba P, Giacò E, Cinquegrana A, Fasoli M, Lanzini A. Addicts with chronic hepatitis C: Difficult to reach, manage or treat? World J Gastroenterol 2013; 19(44): 8011-8019 [PMID: 24307794 DOI: 10.3748/wjg.v19.i44.8011] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
49 Major ME. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses 2009;1:144-65. [PMID: 21994543 DOI: 10.3390/v1020144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
50 Vasanthakumar A, Davis JW, Abunimeh M, Söderholm J, Zha J, Dumas EO, Cohen DE, Waring JF, Lagging M. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. PLoS One 2018;13:e0198296. [PMID: 29851985 DOI: 10.1371/journal.pone.0198296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
51 Jahan S, Samreen B, Khaliq S, Ijaz B, Khan M, Siddique MH, Ahmad W, Hassan S. HCV entry receptors as potential targets for siRNA-based inhibition of HCV. Genet Vaccines Ther. 2011;9:15. [PMID: 21896165 DOI: 10.1186/1479-0556-9-15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
52 Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med 2015;7:11-20. [PMID: 25926761 DOI: 10.2147/HMER.S79584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Kwon JH, Bae SH, Choi JY, Yoon SK, Byun KS, Paik SW, Lim YS, Lee HC, Han KH, Lee KS. Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. Korean J Intern Med 2009;24:203-11. [PMID: 19721856 DOI: 10.3904/kjim.2009.24.3.203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
54 Pybus OG, Barnes E, Taggart R, Lemey P, Markov PV, Rasachak B, Syhavong B, Phetsouvanah R, Sheridan I, Humphreys IS. Genetic history of hepatitis C virus in East Asia. J Virol. 2009;83:1071-1082. [PMID: 18971279 DOI: 10.1128/jvi.01501-08] [Cited by in Crossref: 153] [Cited by in F6Publishing: 92] [Article Influence: 10.9] [Reference Citation Analysis]
55 Sun HY, Chang SY, Yang ZY, Lu CL, Wu H, Yeh CC, Liu WC, Hsieh CY, Hung CC, Chang SC. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol 2012;50:781-7. [PMID: 22189113 DOI: 10.1128/JCM.06014-11] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
56 Sockalingam S, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol. 2013;13:86. [PMID: 23672254 DOI: 10.1186/1471-230x-13-86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
57 Hauser P, Morasco BJ, Linke A, Bjornson D, Ruimy S, Matthews A, Rifai A, Indest DW, Loftis JM. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics. 2009;50:500-505. [PMID: 19855036 DOI: 10.1176/appi.psy.50.5.500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.4] [Reference Citation Analysis]
58 Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006;50:1013-1020. [PMID: 16495264 DOI: 10.1128/aac.50.3.1013-1020.2006] [Cited by in Crossref: 229] [Cited by in F6Publishing: 80] [Article Influence: 14.3] [Reference Citation Analysis]
59 Li PY, Yao L, Guo B, Song JW. Interleukin-28B gene polymorphisms: a new beginning of personalized treatment of hepatitis C. Shijie Huaren Xiaohua Zazhi 2012; 20(2): 119-124 [DOI: 10.11569/wcjd.v20.i2.119] [Reference Citation Analysis]
60 Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011;29:993-1003. [PMID: 22068541 DOI: 10.1038/nbt.2020] [Cited by in Crossref: 203] [Cited by in F6Publishing: 178] [Article Influence: 18.5] [Reference Citation Analysis]
61 Tahata Y, Sakamori R, Takehara T. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. Glob Health Med 2021;3:321-34. [PMID: 34782876 DOI: 10.35772/ghm.2021.01083] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Okushin H, Morii K, Uesaka K, Yuasa S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. World J Hepatol 2010; 2(6): 226-232 [PMID: 21161001 DOI: 10.4254/wjh.v2.i6.226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
63 Gill G, Bajwa H, Strouhal P, Buch HN. Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report. J Med Case Rep 2016;10:253. [PMID: 27632981 DOI: 10.1186/s13256-016-1028-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs 2008;68:27-42. [PMID: 18081371 DOI: 10.2165/00003495-200868010-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
65 Lanford RE, Guerra B, Bigger CB, Lee H, Chavez D, Brasky KM. Lack of response to exogenous interferon-alpha in the liver of chimpanzees chronically infected with hepatitis C virus. Hepatology. 2007;46:999-1008. [PMID: 17668868 DOI: 10.1002/hep.21776] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
66 Heo NY, Lim YS, Lee HC, Lee YS, Kim KM, Byun KS, Han KH, Lee KS, Paik SW, Yoon SK, Suh DJ. High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. Clin Mol Hepatol 2013;19:60-9. [PMID: 23593611 DOI: 10.3350/cmh.2013.19.1.60] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
67 Ning G, Lin CS. History and future of antiviral therapy of chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2016; 24(14): 2117-2130 [DOI: 10.11569/wcjd.v24.i14.2117] [Reference Citation Analysis]
68 Murira A, Lamarre A. Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front Immunol 2016;7:609. [PMID: 28066419 DOI: 10.3389/fimmu.2016.00609] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 8.0] [Reference Citation Analysis]
69 Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16:75-90. [PMID: 18761607 DOI: 10.1111/j.1365-2893.2008.01012.x] [Cited by in Crossref: 176] [Cited by in F6Publishing: 150] [Article Influence: 12.6] [Reference Citation Analysis]
70 Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T; GUARD-C Study Group. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One 2016;11:e0151703. [PMID: 27018988 DOI: 10.1371/journal.pone.0151703] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
71 Benson N, de Jongh J, Duckworth JD, Jones HM, Pertinez HE, Rawal JK, van Steeg TJ, Van der Graaf PH. Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice. Antimicrob Agents Chemother 2010;54:1179-85. [PMID: 20028817 DOI: 10.1128/AAC.00551-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
72 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One. 2011;6:e24514. [PMID: 21935415 DOI: 10.1371/journal.pone.0024514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
73 Paul F, Pellegrini S, Uzé G. IFNA2: The prototypic human alpha interferon. Gene 2015;567:132-7. [PMID: 25982860 DOI: 10.1016/j.gene.2015.04.087] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
74 Cunningham M, Foster GR. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol 2012;5:139-51. [PMID: 22423262 DOI: 10.1177/1756283X11426895] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
75 Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017;17:162. [PMID: 28222681 DOI: 10.1186/s12879-017-2256-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
76 Nguyen TH, Guedj J, Yu J, Levi M, Mentré F. Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome. CPT Pharmacometrics Syst Pharmacol 2013;2:e56. [PMID: 23863865 DOI: 10.1038/psp.2013.31] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
77 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
78 Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol 2015; 7(26): 2688-2695 [PMID: 26609346 DOI: 10.4254/wjh.v7.i26.2688] [Reference Citation Analysis]
79 Nunes D, Saitz R, Libman H, Cheng DM, Vidaver J, Samet JH. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res. 2006;30:1520-1526. [PMID: 16930214 DOI: 10.1111/j.1530-0277.2006.00183.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.4] [Reference Citation Analysis]
80 Martin CK, Hostetter JE, Hagan JJ. New opportunities for the management and therapy of hepatitis C in correctional settings. Am J Public Health. 2010;100:13-17. [PMID: 20007626 DOI: 10.2105/ajph.2008.147629] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
81 Milan M, Boninsegna S, Scribano L, Lobello S, Fagiuoli S, Fabris P, Buda A, Martines D. Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients? Infection. 2012;40:173-179. [PMID: 22095532 DOI: 10.1007/s15010-011-0219-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
82 Yuan HJ, Jain M, Snow KK, Gale M, Lee WM. Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy*. J Viral Hepat. 2010;17:208-216. [PMID: 19656286 DOI: 10.1111/j.1365-2893.2009.01169.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
83 Cooper CL, Ahluwalia NK, Efler SM, Vollmer J, Krieg AM, Davis HL. Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. J Immune Based Ther Vaccines 2008;6:3. [PMID: 18541039 DOI: 10.1186/1476-8518-6-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
84 de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One 2012;7:e31016. [PMID: 22328925 DOI: 10.1371/journal.pone.0031016] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
85 Mindikoglu AL, Miller RR. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol. 2009;7:128-34; quiz 124. [PMID: 19084480 DOI: 10.1016/j.cgh.2008.07.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
86 Helal SF, Gomaa HE, Thabet EH, Younan MA, Helmy NA. Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 2014;7:19-24. [PMID: 24833945 DOI: 10.4137/CGast.S13658] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
87 Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol. 2014;49:748-754. [PMID: 23689989 DOI: 10.1007/s00535-013-0826-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
88 Nakayama M, Kobayashi H, Fukushima K, Ishido M, Komada Y, Yoshizawa K. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int 2016;10:158-68. [PMID: 26264253 DOI: 10.1007/s12072-015-9654-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Sulyok M, Makara M, Újhelyi E, Vályi-Nagy I. Non-Hodgkin lymphoma and hepatitis C: where we are and what next? Pathol Oncol Res. 2015;21:1-7. [PMID: 25273531 DOI: 10.1007/s12253-014-9845-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
90 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
91 Qiao J, Yu J, Yang H, Wei H. PCR-based in vitro synthesis of hepatitis C virus NS3 protease for rapid phenotypic resistance testing of protease inhibitors. J Clin Microbiol 2014;52:1139-45. [PMID: 24452171 DOI: 10.1128/JCM.03257-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L; ANRS CO20-CUPIC study group. Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS One 2015;10:e0145105. [PMID: 26670100 DOI: 10.1371/journal.pone.0145105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
93 Kagawa T, Keeffe EB. Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat 2010;2010:562578. [PMID: 21188198 DOI: 10.1155/2010/562578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
94 Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. World J Gastroenterol 2009; 15(47): 5946-5952 [PMID: 20014458 DOI: 10.3748/wjg.15.5946] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Banerjee SS, Aher N, Patil R, Khandare J. Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications. J Drug Deliv 2012;2012:103973. [PMID: 22645686 DOI: 10.1155/2012/103973] [Cited by in Crossref: 137] [Cited by in F6Publishing: 134] [Article Influence: 13.7] [Reference Citation Analysis]
96 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
97 Kwo PY, Badshah MB. Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature. Curr Gastroenterol Rep 2015;17:462. [PMID: 26342813 DOI: 10.1007/s11894-015-0462-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
98 Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14(47): 7149-7159 [PMID: 19084927 DOI: 10.3748/wjg.14.7149] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 85] [Article Influence: 6.1] [Reference Citation Analysis]
99 Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F. Genetic diversity of the hepatitis C virus: Impact and issues in the antiviral therapy. World J Gastroenterol 2007; 13(17): 2416-2426 [PMID: 17552024 DOI: 10.3748/wjg.v13.i17.2416] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
100 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
101 Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. Cell Host Microbe 2009;6:513-22. [PMID: 20006840 DOI: 10.1016/j.chom.2009.11.004] [Cited by in Crossref: 167] [Cited by in F6Publishing: 156] [Article Influence: 13.9] [Reference Citation Analysis]
102 Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH, Hudson ML, Howell CD, Talloen W, Bollekens J, De Wit M, Scholliers A, Fried MW. Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011;53:14-22. [PMID: 21254158 DOI: 10.1002/hep.24056] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
103 Wise M, Finelli L, Sorvillo F. Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data. Public Health Rep 2010;125:414-22. [PMID: 20433036 DOI: 10.1177/003335491012500310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
104 Shapshak P, Somboonwit C, Drumright LN, Frost SD, Commins D, Tellinghuisen TL, Scott WK, Duncan R, McCoy C, Page JB, Giunta B, Fernandez F, Singer E, Levine A, Minagar A, Oluwadara O, Kotila T, Chiappelli F, Sinnott JT. Molecular and contextual markers of hepatitis C virus and drug abuse. Mol Diagn Ther 2009;13:153-79. [PMID: 19650670 DOI: 10.2165/01250444-200913030-00002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
105 Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, Afkhamizarreh F, Durocher Y. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol 2008;8:65. [PMID: 18752669 DOI: 10.1186/1472-6750-8-65] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
106 Salmerón J, De Rueda PM, Ruiz-Extremera A, Casado J, Huertas C, Bernal Mdel C, Rodríguez L, Palacios A. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C. Dig Dis Sci 2006;51:960-7. [PMID: 16758308 DOI: 10.1007/s10620-006-9347-2] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
107 Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C infection. BMJ 2006;332:1013-7. [PMID: 16644828 DOI: 10.1136/bmj.332.7548.1013] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
108 Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis C virus infection in females compared with males. Gut 2006;55:1183-7. [PMID: 16434426 DOI: 10.1136/gut.2005.078147] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
109 Fujita N, Nakanishi M, Mukai J, Naito Y, Ichida T, Kaito M, Yoshikawa T, Takei Y. Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis. Mol Med 2011;17:70-8. [PMID: 20927485 DOI: 10.2119/molmed.2010.00124] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
110 Singh A, Gupta V. SARS-CoV-2 therapeutics: how far do we stand from a remedy? Pharmacol Rep 2021;73:750-68. [PMID: 33389724 DOI: 10.1007/s43440-020-00204-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
111 Carreño V, Bartolomé J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol 2012; 18(23): 2887-2894 [PMID: 22736911 DOI: 10.3748/wjg.v18.i23.2887] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
112 Tani J, Morishita A, Sakamoto T, Takuma K, Nakahara M, Fujita K, Oura K, Tadokoro T, Mimura S, Nomura T, Yoneyama H, Kobara H, Himoto T, Tsutsui A, Senoh T, Nagano T, Ogawa C, Moriya A, Deguchi A, Takaguchi K, Masaki T. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205-2212. [PMID: 32194718 DOI: 10.3892/ol.2020.11341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
113 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
114 Taniguchi M, Tasaka-Fujita M, Nakagawa M, Watanabe T, Kawai-Kitahata F, Otani S, Goto F, Nagata H, Kaneko S, Nitta S, Murakawa M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Mori K, Yagi S, Kakinuma S, Asahina Y, Watanabe M. Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. J Clin Transl Hepatol 2016;4:5-11. [PMID: 27047766 DOI: 10.14218/JCTH.2015.00047] [Reference Citation Analysis]
115 Campos-Varela I, Lai JC, Verna EC, O'Leary JG, Todd Stravitz R, Forman LM, Trotter JF, Brown RS, Terrault NA; Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Hepatitis C genotype influences post-liver transplant outcomes. Transplantation 2015;99:835-40. [PMID: 25211520 DOI: 10.1097/TP.0000000000000413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
116 Quer J, Buti M, Cubero M, Guardia J, Esteban R, Esteban JI. New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Infect Drug Resist 2010;3:133-45. [PMID: 21694902 DOI: 10.2147/IDR.S7136] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
117 Groessl EJ, Weingart KR, Kaplan RM, Clark JA, Gifford AL, Ho SB. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med 2008;23:1959-65. [PMID: 18807097 DOI: 10.1007/s11606-008-0790-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
118 Manrai M, Dawra S, Kapoor R, Srivastava S, Singh A. Anemia in cirrhosis: An underestimated entity. World J Clin Cases 2022; 10(3): 777-789 [DOI: 10.12998/wjcc.v10.i3.777] [Reference Citation Analysis]
119 Gaglio PJ, Moss N, McGaw C, Reinus J. Direct-acting antiviral therapy for hepatitis C: attitudes regarding future use. Dig Dis Sci 2011;56:1509-15. [PMID: 21336604 DOI: 10.1007/s10620-011-1604-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
120 Chen JY, Chung RT. Future classes of hepatitis C virus therapeutic agents. Infect Dis Clin North Am 2012;26:949-66. [PMID: 23083826 DOI: 10.1016/j.idc.2012.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
121 Alazard-Dany N, Denolly S, Boson B, Cosset FL. Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets. Viruses. 2019;11. [PMID: 30621318 DOI: 10.3390/v11010030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
122 Kim S, Han KH, Ahn SH. Hepatitis C Virus and Antiviral Drug Resistance. Gut Liver 2016;10:890-5. [PMID: 27784846 DOI: 10.5009/gnl15573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
123 Pichetshote N, Groessl E, Yee H, Ho SB. Optimizing the dose and duration of therapy for chronic hepatitis C. Gut Liver 2009;3:1-13. [PMID: 20479894 DOI: 10.5009/gnl.2009.3.1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Plemper RK. Measles Resurgence and Drug Development. Curr Opin Virol 2020;41:8-17. [PMID: 32247280 DOI: 10.1016/j.coviro.2020.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
125 Bock JA, Fairley KJ, Smith RE, Maeng DD, Pitcavage JM, Inverso NA, Williams MS. Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection. Public Health Genomics 2014;17:306-19. [PMID: 25247313 DOI: 10.1159/000365939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
126 Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 2009;23:2439-50. [PMID: 19898214 DOI: 10.1097/QAD.0b013e32832ff1c0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
127 Ebinuma H, Saito H, Tada S, Nakamoto N, Ohishi T, Tsunematsu S, Kumagai N, Tsuchimoto K, Tsukada N, Inagaki Y. Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. Hepatol Int. 2011;Epub ahead of print. [PMID: 22020828 DOI: 10.1007/s12072-011-9312-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
128 Witkos M, Yi QL, Heathcote J, Kapral MK, Krahn MD. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 2006;20:107-11. [PMID: 16482237 DOI: 10.1155/2006/638272] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
129 Kamp WM, Sellers CM, Stein S, Lim JK, Kim HS. Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. Sci Rep 2019;9:17081. [PMID: 31745132 DOI: 10.1038/s41598-019-53051-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
130 Moreno-Otero R, Trapero-Marugán M, Gómez-Domínguez E, García-Buey L, Moreno-Monteagudo J. Is interferon-beta an alternative treatment for chronic hepatitis C. World J Gastroenterol 2006; 12(17): 2730-2736 [PMID: 16718760 DOI: 10.3748/wjg.v12.i17.2730] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
131 Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Investig 2013;33:325-31. [PMID: 23532802 DOI: 10.1007/s40261-013-0074-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
132 Heathcote J, Ramji A. When to treat patients with chronic hepatitis C. Curr Gastroenterol Rep 2004;6:261-3. [PMID: 15245691 DOI: 10.1007/s11894-004-0074-6] [Reference Citation Analysis]
133 Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurol 2014;14:240. [PMID: 25551571 DOI: 10.1186/s12883-014-0240-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
134 Nemr N, Kishk R, Mandour M. Role of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. Indian J Gastroenterol 2016;35:7-13. [PMID: 26880169 DOI: 10.1007/s12664-016-0618-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
135 Wietzke-Braun P, Meier V, Neubauer-Saile K, Mihm S, Ramadori G. Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients. World J Gastroenterol 2005; 11(39): 6188-6192 [PMID: 16273648 DOI: 10.3748/wjg.v11.i39.6188] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
136 Yasin T, Riley TR, Schreibman IR. Current treatment of choice for chronic hepatitis C infection. Infect Drug Resist. 2011;4:11-18. [PMID: 21694905 DOI: 10.2147/IDR.S4827] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
137 He XS, Nanda S, Ji X, Calderon-Rodriguez GM, Greenberg HB, Liang TJ. Differential transcriptional responses to interferon-alpha and interferon-gamma in primary human hepatocytes. J Interferon Cytokine Res 2010;30:311-20. [PMID: 20038212 DOI: 10.1089/jir.2009.0082] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
138 Ahmad W, Ijaz B, Javed FT, Kausar H, Sarwar MT, Gull S, Asad S, Shahid I, Hassan S. HCV genotype-specific correlation with serum markers: higher predictability for genotype 4a. Virol J 2011;8:293. [PMID: 21663629 DOI: 10.1186/1743-422X-8-293] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
139 El Kassas M, Alboraie M, Naguib M, Omar H, Tahan AE, Moaz I, Abdellah M, Ezzat S, Wifi MN, Sherief AF, Eltabbakh M, Abdelsalam L, Eissa AH, Omran D. A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. Turk J Gastroenterol 2019;30:708-13. [PMID: 31418415 DOI: 10.5152/tjg.2019.18514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Helal GK, Gad MA, Abd-Ellah MF, Eid MS. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients. J Med Virol 2016;88:2170-8. [PMID: 27183377 DOI: 10.1002/jmv.24575] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
141 Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. PLoS One 2015;10:e0125400. [PMID: 25938236 DOI: 10.1371/journal.pone.0125400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
142 Lotrich FE, Sears B, McNamara RK. Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids. J Psychosom Res 2013;75:475-83. [PMID: 24182638 DOI: 10.1016/j.jpsychores.2013.07.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
143 Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol 2009;2:205-19. [PMID: 21180544 DOI: 10.1177/1756283X09336045] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
144 Kawano A, Shigematsu H, Miki K, Ichiki Y, Morita C, Yanagita K, Takahashi K, Dohmen K, Nomura H, Ishibashi H, Shimoda S. Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Intern Med 2018;57:1533-42. [PMID: 29321441 DOI: 10.2169/internalmedicine.9857-17] [Reference Citation Analysis]
145 Hall EW, Rosenberg ES, Sullivan PS. Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010. BMC Infect Dis 2018;18:224. [PMID: 29769036 DOI: 10.1186/s12879-018-3133-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
146 Karchava M, Sharvadze L, Chkhartishvili N, Nelson K, Gochitashivli N, Gatserelia L, Dvali N, Dolmazashvili E, Dzigua L, Badridze N. IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Eur J Gastroenterol Hepatol. 2012;24:817-823. [PMID: 22569080 DOI: 10.1097/meg.0b013e328353fd11] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
147 Dhillon R, Rossi S, Herrine SK. Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients. Ther Clin Risk Manag 2008;4:789-96. [PMID: 19209261 DOI: 10.2147/tcrm.s2093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
148 Sapra S, Chang E, Broder MS, L'Italien G. Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study. BMC Health Serv Res 2014;14:429. [PMID: 25249187 DOI: 10.1186/1472-6963-14-429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
149 Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Dis. 2008;14:10-14. [PMID: 18173443 DOI: 10.1111/j.1601-0825.2007.01419.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
150 Mikocka-Walus AA. Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders. World J Gastrointest Pharmacol Ther 2010; 1(2): 64-71 [PMID: 21577298 DOI: 10.4292/wjgpt.v1.i2.64] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
151 Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S, Sarrazin C, von Hahn T. Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cell Mol Gastroenterol Hepatol 2015;1:285-294.e1. [PMID: 28210681 DOI: 10.1016/j.jcmgh.2015.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
152 Heo NY, Lim YS, Lee W, Oh M, An J, Lee D, Shim JH, Kim KM, Lee HC, Lee YS, Suh DJ. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. Clin Mol Hepatol 2014;20:177-84. [PMID: 25032184 DOI: 10.3350/cmh.2014.20.2.177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
153 Howe AY, Bloom J, Baldick CJ, Benetatos CA, Cheng H, Christensen JS, Chunduru SK, Coburn GA, Feld B, Gopalsamy A, Gorczyca WP, Herrmann S, Johann S, Jiang X, Kimberland ML, Krisnamurthy G, Olson M, Orlowski M, Swanberg S, Thompson I, Thorn M, Del Vecchio A, Young DC, van Zeijl M, Ellingboe JW, Upeslacis J, Collett M, Mansour TS, O'Connell JF. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2004;48:4813-21. [PMID: 15561861 DOI: 10.1128/AAC.48.12.4813-4821.2004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
154 Smith JA, Aberle JH, Fleming VM, Ferenci P, Thomson EC, Karayiannis P, McLean AR, Holzmann H, Klenerman P. Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis 2010;202:1770-9. [PMID: 21067369 DOI: 10.1086/657317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
155 Toniutto P, Fabris C, Bitetto D, Fornasiere E, Fumolo E, Rapetti R, Pirisi M. Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantation. Ther Clin Risk Manag 2008;4:599-603. [PMID: 18827855 DOI: 10.2147/tcrm.s2661] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
156 Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, Andersen J, Currier JS. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010;55:170-5. [PMID: 20622678 DOI: 10.1097/QAI.0b013e3181e36420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
157 Brogan AJ, Talbird SE, Thompson JR, Miller JD, Rubin J, Deniz B. Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One 2014;9:e90295. [PMID: 24603445 DOI: 10.1371/journal.pone.0090295] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
158 Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-35. [PMID: 16299039 DOI: 10.1136/gut.2005.069674] [Cited by in Crossref: 204] [Cited by in F6Publishing: 202] [Article Influence: 12.0] [Reference Citation Analysis]
159 Abd El-Kader SM, Al-Jiffri OH, Al-Shreef FM. Liver enzymes and psychological well-being response to aerobic exercise training in patients with chronic hepatitis C. Afr Health Sci 2014;14:414-9. [PMID: 25320592 DOI: 10.4314/ahs.v14i2.18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
160 Veldt BJ, Saracco G, Boyer N, Cammà C, Bellobuono A, Hopf U, Castillo I, Weiland O, Nevens F, Hansen BE. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut. 2004;53:1504-1508. [PMID: 15361504 DOI: 10.1136/gut.2003.038257] [Cited by in Crossref: 119] [Cited by in F6Publishing: 112] [Article Influence: 6.6] [Reference Citation Analysis]
161 Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75. [PMID: 22720279 DOI: 10.1155/2012/947676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
162 Wagner G, Chan Osilla K, Garnett J, Ghosh-Dastidar B, Bhatti L, Goetz MB, Witt M. Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Res Treat 2011;2011:903480. [PMID: 22110904 DOI: 10.1155/2011/903480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
163 Wang HC, Ren YP, Qiu Y, Zheng J, Li GL, Hu CP, Zhou TY, Lu W, Li L. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 2018;39:140-53. [PMID: 28880015 DOI: 10.1038/aps.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
164 Kim CS, Jung JH, Wakita T, Yoon SK, Jang SK. Monitoring the antiviral effect of alpha interferon on individual cells. J Virol 2007;81:8814-20. [PMID: 17537862 DOI: 10.1128/JVI.02824-06] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
165 Takeshita M, Ishida Y, Akamatsu E, Ohmori Y, Sudoh M, Uto H, Tsubouchi H, Kataoka H. Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem. 2009;284:21165-21176. [PMID: 19531480 DOI: 10.1074/jbc.m109.004945] [Cited by in Crossref: 76] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
166 Sharafi H, Alavian SM, Keshvari M. Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. Hepat Mon. 2015;15:e24955. [PMID: 25741374 DOI: 10.5812/hepatmon.24955] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
167 Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y. The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients. BMC Res Notes 2012;5:135. [PMID: 22405406 DOI: 10.1186/1756-0500-5-135] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
168 Aparicio E, Parera M, Franco S, Pérez-Alvarez N, Tural C, Clotet B, Martínez MA. IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One. 2010;5:e13771. [PMID: 21048934 DOI: 10.1371/journal.pone.0013771] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
169 Manso CF, Bibby DF, Lythgow K, Mohamed H, Myers R, Williams D, Piorkowska R, Chan YT, Bowden R, Ansari MA, Ip CLC, Barnes E, Bradshaw D, Mbisa JL. Technical Validation of a Hepatitis C Virus Whole Genome Sequencing Assay for Detection of Genotype and Antiviral Resistance in the Clinical Pathway. Front Microbiol 2020;11:576572. [PMID: 33162957 DOI: 10.3389/fmicb.2020.576572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
170 Vermehren J, Colucci G, Gohl P, Hamdi N, Abdelaziz AI, Karey U, Thamke D, Zitzer H, Zeuzem S, Sarrazin C. Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol. 2011;49:3309-3315. [PMID: 21752967 DOI: 10.1128/jcm.00602-11] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
171 Lattimore S, Irving W, Collins S, Penman C, Ramsay M; Collaboration for the Sentinel Surveillance of Blood-Borne Virus Testing. Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection. Hepatology 2014;59:1343-50. [PMID: 24214920 DOI: 10.1002/hep.26926] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
172 Lo Re V 3rd, Amorosa VK, Localio AR, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009;48:186-93. [PMID: 19086908 DOI: 10.1086/595685] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
173 Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, Francica S, Cavallo R, Alpa M. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol. 2008;34:111-117. [PMID: 18270864 DOI: 10.1007/s12016-007-8019-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
174 Karino T, Ozeki I, Hige S, Kimura M, Arakawa T, Nakajima T, Kuwata Y, Sato T, Ohmura T, Toyota J. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat. 2014;21:341-347. [PMID: 24001168 DOI: 10.1111/jvh.12162] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
175 Rodríguez-Iñigo E, López-Alcorocho JM, Bartolomé J, Ortiz-Movilla N, Pardo M, Carreño V. Percentage of hepatitis C virus-infected hepatocytes is a better predictor of response than serum viremia levels. J Mol Diagn 2005;7:535-43. [PMID: 16237224 DOI: 10.1016/S1525-1578(10)60585-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
176 Gross JB. Nonresponders to Previous Chronic Hepatitis C Treatment. Curr Treat Options Gastroenterol 2004;7:469-75. [PMID: 15527713 DOI: 10.1007/s11938-004-0006-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
177 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.3] [Reference Citation Analysis]
178 Blight KJ, McKeating JA, Marcotrigiano J, Rice CM. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol. 2003;77:3181-3190. [PMID: 12584342 DOI: 10.1128/jvi.77.5.3181-3190.2003] [Cited by in Crossref: 264] [Cited by in F6Publishing: 132] [Article Influence: 13.9] [Reference Citation Analysis]
179 Peltekian KM, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Balshaw R, Deschênes M. Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Annals of Hepatology 2011;10:260-9. [DOI: 10.1016/s1665-2681(19)31537-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
180 Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009;7:219-226. [PMID: 19068241 DOI: 10.1016/j.cgh.2008.10.034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
181 Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res 2016;5:2061. [PMID: 27746906 DOI: 10.12688/f1000research.9114.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Bunchorntavakul C, Mitrani R, Reddy KR. Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road? J Clin Exp Hepatol. 2018;8:81-94. [PMID: 29743799 DOI: 10.1016/j.jceh.2017.11.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
183 Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2003;63:701-730. [PMID: 12656650 DOI: 10.2165/00003495-200363070-00008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
184 Khalili M, Bernstein D, Lentz E, Barylski C, Hoffman-Terry M. Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. Dig Dis Sci 2005;50:1148-55. [PMID: 15986873 DOI: 10.1007/s10620-005-2723-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
185 Young AM, Crosby RA, Oser CB, Leukefeld CG, Stephens DB, Havens JR. Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012;84:1376-87. [PMID: 22825816 DOI: 10.1002/jmv.23252] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
186 Aljumah AA, Saeed MA, Al Flaiw AI, Al Traif IH, Al Alwan AM, Al Qurashi SH, Al Ghamdi GA, Al Hejaili FF, Al Balwi MA, Al Sayyari AA. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J Gastroenterol 2012; 18(1): 55-63 [PMID: 22228971 DOI: 10.3748/wjg.v18.i1.55] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
187 Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941-953. [PMID: 24626851 DOI: 10.1007/s00535-014-0949-8] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
188 Mustafa M, Hussain S, Qureshi S, Malik SA, Kazmi AR, Naeem M. Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients. BMC Gastroenterol 2012;12:117. [PMID: 22925702 DOI: 10.1186/1471-230X-12-117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
189 Lazear HM, Schoggins JW, Diamond MS. Shared and Distinct Functions of Type I and Type III Interferons. Immunity 2019;50:907-23. [PMID: 30995506 DOI: 10.1016/j.immuni.2019.03.025] [Cited by in Crossref: 267] [Cited by in F6Publishing: 252] [Article Influence: 89.0] [Reference Citation Analysis]
190 McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, Symons J, Cammack N, Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-12. [PMID: 18285474 DOI: 10.1128/AAC.01317-07] [Cited by in Crossref: 134] [Cited by in F6Publishing: 61] [Article Influence: 9.6] [Reference Citation Analysis]
191 Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. [PMID: 21449783 DOI: 10.1056/NEJMoa1010494] [Cited by in Crossref: 1849] [Cited by in F6Publishing: 729] [Article Influence: 168.1] [Reference Citation Analysis]
192 Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis. 2011;11:208. [PMID: 21810243 DOI: 10.1186/1471-2334-11-208] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
193 Loftfield E, O'Brien TR, Pfeiffer RM, Howell CD, Horst R, Prokunina-Olsson L, Weinstein SJ, Albanes D, Morgan TR, Freedman ND. Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials. PLoS One 2016;11:e0166036. [PMID: 27832143 DOI: 10.1371/journal.pone.0166036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
194 Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, Chien RN. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis 2015;15:156. [PMID: 25888020 DOI: 10.1186/s12879-015-0888-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
195 García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C. Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C. World J Gastroenterol 2013; 19(12): 1943-1952 [PMID: 23569340 DOI: 10.3748/wjg.v19.i12.1943] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
196 Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH. Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012;19:47-54. [PMID: 21129131 DOI: 10.1111/j.1365-2893.2010.01411.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
197 Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174 [PMID: 26290644 DOI: 10.3748/wjg.v21.i30.9163] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
198 Hsieh YC, Jeng WJ, Huang CH, Teng W, Chen WT, Chen YC, Lin SM, Tai DI, Lin CY, Sheen IS. Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. PLoS One 2018;13:e0202777. [PMID: 30138456 DOI: 10.1371/journal.pone.0202777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
199 Chang SC, Yang SS, Chang CC, Lin CC, Chung YC, Li TC. Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ. Health Qual Life Outcomes. 2014;12:97. [PMID: 24941994 DOI: 10.1186/1477-7525-12-97] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
200 Sagir A, Adams O, Kirschberg O, Erhardt A, Heintges T, Häussinger D. SEN virus does not affect treatment response in hepatitis C virus coinfected patients but SEN virus response depends on SEN virus DNA concentration. World J Gastroenterol 2004; 10(13): 1893-1897 [PMID: 15222031 DOI: 10.3748/wjg.v10.i13.1893] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
201 Tong J, Wang YW, Lu YA. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J Zhejiang Univ Sci B 2012;13:56-82. [PMID: 22205621 DOI: 10.1631/jzus.B1100120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
202 Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro R, Sata M. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci. 2006;51:808-812. [PMID: 16615008 DOI: 10.1007/s10620-006-3211-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
203 Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T. High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment. Hepatol Res 2015;45:1292-8. [PMID: 25689487 DOI: 10.1111/hepr.12505] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
204 Lin CC, Xu C, Zhu N, Yeh LT. Absorption, metabolism, and excretion of [14C]viramidine in humans. Antimicrob Agents Chemother 2006;50:2368-73. [PMID: 16801414 DOI: 10.1128/AAC.00118-06] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
205 Sallie R. Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. Virol J 2007;4:29. [PMID: 17355620 DOI: 10.1186/1743-422X-4-29] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
206 Monje-Agudo P, Castro-Iglesias A, Rivero-Juárez A, Martínez-Marcos F, Ortega-González E, Real LM, Pernas B, Merchante N, Cid P, Macías J, Merino MD, Rivero A, Mena A, Neukam K, Pineda JA; Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. Eur J Clin Microbiol Infect Dis 2015;34:1929-36. [PMID: 26155784 DOI: 10.1007/s10096-015-2434-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
207 Mizuta T, Kawaguchi Y, Eguchi Y, Takahashi H, Ario K, Akiyama T, Oza N, Otsuka T, Kuwashiro T, Yoshimura T. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci. 2010;55:183-189. [PMID: 19184426 DOI: 10.1007/s10620-008-0691-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
208 Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol 2008; 14(40): 6140-6144 [PMID: 18985803 DOI: 10.3748/wjg.14.6140] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
209 Luo Y, Zhang Y, Wang D, Shen D, Che YQ. Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection - A Real-World Cohort Study. Cancer Manag Res 2020;12:5323-30. [PMID: 32753950 DOI: 10.2147/CMAR.S254580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Ishikane M, Watanabe K, Tsukada K, Nozaki Y, Yanase M, Igari T, Masaki N, Kikuchi Y, Oka S, Gatanaga H. Acute hepatitis C in HIV-1 infected Japanese Cohort: single center retrospective cohort study. PLoS One 2014;9:e100517. [PMID: 24945812 DOI: 10.1371/journal.pone.0100517] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
211 Jeng WJ, Lin CY, Chen JY, Huang CW, Huang CH, Sheen IS. None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. PLoS One 2012;7:e48217. [PMID: 23173032 DOI: 10.1371/journal.pone.0048217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
212 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
213 Backus LI, Gavrilov S, Loomis TP, Halloran JP, Phillips BR, Belperio PS, Mole LA. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16:775-783. [PMID: 19717794 DOI: 10.1197/jamia.m3203] [Cited by in Crossref: 79] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
214 Chung RT, Gale M, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 2008;47:306-320. [PMID: 18161743 DOI: 10.1002/hep.22070] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
215 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
216 Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602. [PMID: 21037988 DOI: 10.1155/2010/717845] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
217 Elfiky AA, Mahran HA, Ibrahim IM, Ibrahim MN, Elshemey WM. Molecular dynamics simulations and MM-GBSA reveal novel guanosine derivatives against SARS-CoV-2 RNA dependent RNA polymerase. RSC Adv 2022;12:2741-50. [DOI: 10.1039/d1ra07447d] [Reference Citation Analysis]
218 Dahari H, Layden-Almer JE, Kallwitz E, Ribeiro RM, Cotler SJ, Layden TJ, Perelson AS. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 2009;136:1402-9. [PMID: 19208338 DOI: 10.1053/j.gastro.2008.12.060] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
219 Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14(42): 6467-6472 [PMID: 19030197 DOI: 10.3748/wjg.14.6467] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
220 Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Pürstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2011;55:4196-203. [PMID: 21746939 DOI: 10.1128/AAC.00307-11] [Cited by in Crossref: 67] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
221 Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059 [PMID: 27672299 DOI: 10.3748/wjg.v22.i35.8050] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
222 Morello J, Soriano V, Barreiro P, Medrano J, Madejón A, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, Rodríguez-Novoa S. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother 2010;54:1647-9. [PMID: 20100874 DOI: 10.1128/AAC.01399-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
223 Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C; AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459. [PMID: 15282352 DOI: 10.1056/nejmoa032653] [Cited by in Crossref: 675] [Cited by in F6Publishing: 195] [Article Influence: 37.5] [Reference Citation Analysis]
224 Ravi S, Nasiri Toosi M, Karimzadeh I, Ahadi-Barzoki M, Khalili H. Adherence to chronic hepatitis C treatment regimen: first report from a referral center in iran. Hepat Mon 2013;13:e11038. [PMID: 24032043 DOI: 10.5812/hepatmon.11038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
225 Fu R, Gutfraind A, Brandeau ML. Modeling a dynamic bi-layer contact network of injection drug users and the spread of blood-borne infections. Math Biosci 2016;273:102-13. [PMID: 26775738 DOI: 10.1016/j.mbs.2016.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
226 Serumondo J, Penkunas MJ, Niyikora J, Ngwije A, Kiromera A, Musabeyezu E, Umutesi J, Umuraza S, Musengimana G, Nsanzimana S. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators. BMC Public Health 2020;20:946. [PMID: 32546216 DOI: 10.1186/s12889-020-09000-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
227 Puoti M, Zanini B, Quinzan GP, Ravasio L, Paraninfo G, Santantonio T, Rollo A, Artioli S, Maggiolo F, Zaltron S, Raise E, Mignani E, Resta F, Verucchi G, Pastore G, Suter F, Carosi G; MASTER HIV/HCV Co-Infection Study Group. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. J Hepatol 2004;41:312-8. [PMID: 15288482 DOI: 10.1016/j.jhep.2004.04.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
228 Pouliot JJ, Thomson M, Xie M, Horton J, Johnson J, Krull D, Mathis A, Morikawa Y, Parks D, Peterson R, Shimada T, Thomas E, Vamathevan J, Van Horn S, Xiong Z, Hamatake R, Peat AJ. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein. Antimicrob Agents Chemother 2015;59:6539-50. [PMID: 26259798 DOI: 10.1128/AAC.00813-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
229 Poordad F. Big changes are coming in hepatitis C. Curr Gastroenterol Rep 2011;13:72-7. [PMID: 21063814 DOI: 10.1007/s11894-010-0153-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
230 He CL, Liu M, Tan ZX, Hu YJ, Zhang QY, Kuang XM, Kong WL, Mao Q. Hepatitis C virus core protein-induced miR-93-5p up-regulation inhibits interferon signaling pathway by targeting IFNAR1. World J Gastroenterol 2018; 24(2): 226-236 [PMID: 29375208 DOI: 10.3748/wjg.v24.i2.226] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
231 Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau Ponty J, Sabot D, Kerever A, Valleur M, Poynard T. Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract. 2010;2010. [PMID: 20811482 DOI: 10.1155/2010/261472] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
232 Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41-48. [PMID: 15669887 DOI: 10.4088/jcp.v66n0106] [Cited by in Crossref: 213] [Cited by in F6Publishing: 83] [Article Influence: 12.5] [Reference Citation Analysis]
233 Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19:105-123. [PMID: 15697325 DOI: 10.2165/00023210-200519020-00002] [Cited by in Crossref: 331] [Cited by in F6Publishing: 290] [Article Influence: 19.5] [Reference Citation Analysis]
234 Carroll SS, Ludmerer S, Handt L, Koeplinger K, Zhang NR, Graham D, Davies ME, MacCoss M, Hazuda D, Olsen DB. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 2009;53:926-34. [PMID: 19075052 DOI: 10.1128/AAC.01032-08] [Cited by in Crossref: 69] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
235 Khattar R, Luft O, Yavorska N, Shalev I, Phillips MJ, Adeyi O, Gao D, Bartczak A, Urbanellis P, Shyu W, Zhang J, Manuel J, Levy GA, Selzner N. Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. PLoS One 2013;8:e72309. [PMID: 24146739 DOI: 10.1371/journal.pone.0072309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
236 Manvar D, Mishra M, Kumar S, Pandey VN. Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba. J Ethnopharmacol 2012;144:545-54. [PMID: 23026306 DOI: 10.1016/j.jep.2012.09.036] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
237 Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol 2017; 9(36): 1340-1345 [PMID: 29359017 DOI: 10.4254/wjh.v9.i36.1340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
238 Tillmann HL. Hepatitis C virus infection and the brain. Metab Brain Dis. 2004;19:351-356. [PMID: 15554427 DOI: 10.1023/b: mebr.0000043981.89134.39] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.53/j.gastro.2009.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
240 Mukaide M, Tanaka Y, Kakuda H, Fujiwara K, Kurbanov F, Orito E, Yoshioka K, Fujise K, Harada S, Kozaki T, Takemura K, Hikiji K, Mizokami M. New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0. World J Gastroenterol 2005; 11(4): 469-475 [PMID: 15641128 DOI: 10.3748/wjg.v11.i4.469] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
241 Lee CC, Su YC, Ko TP, Lin LL, Yang CY, Chang SS, Roffler SR, Wang AH. Structural basis of polyethylene glycol recognition by antibody. J Biomed Sci 2020;27:12. [PMID: 31907057 DOI: 10.1186/s12929-019-0589-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
242 Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol. 2002;76:11079-11090. [PMID: 12368350 DOI: 10.1128/jvi.76.21.11079-11090.2002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
243 Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, Tanaka Y, Matsumoto N, Okuse C, Itoh F, Yokomaku Y, Watanabe T. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. Clin J Gastroenterol 2017;10:41-6. [PMID: 27766544 DOI: 10.1007/s12328-016-0693-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
244 Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg. 2004;8:120-126. [PMID: 14746844 DOI: 10.1016/j.gassur.2003.10.009] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 3.4] [Reference Citation Analysis]
245 Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49:138-147. [PMID: 24005956 DOI: 10.1007/s00535-013-0875-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
246 Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One 2015;10:e0126984. [PMID: 25974722 DOI: 10.1371/journal.pone.0126984] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
247 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
248 Aissa Larousse J, Trimoulet P, Recordon Pinson P, Tauzin B, Azzouz MM, Ben Mami N, Cheikh I, Triki H, Fleury H. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia. Virol J 2015;12:84. [PMID: 26047611 DOI: 10.1186/s12985-015-0318-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
249 Cowan ML, Thomas HC, Foster GR. Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. Clin Med (Lond) 2011;11:184-9. [PMID: 21526708 DOI: 10.7861/clinmedicine.11-2-184] [Reference Citation Analysis]
250 Siatkosky LL, Shermock KM, Younossi ZM. Investigational pharmacologic treatment for liver disease. Expert Opin Investig Drugs 2002;11:1281-93. [PMID: 12225249 DOI: 10.1517/13543784.11.9.1281] [Reference Citation Analysis]
251 Costiniuk CT, Mills E, Cooper CL. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008;22:376-80. [PMID: 18414712 DOI: 10.1155/2008/725702] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
252 Suzuki K, Tamano M, Katayama Y, Kuniyoshi T, Kagawa K, Takada H, Suzuki K. Study of pruritus in chronic hepatitis C patients. World J Gastroenterol 2014; 20(47): 17877-17882 [PMID: 25548485 DOI: 10.3748/wjg.v20.i47.17877] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
253 Kikkawa Y, Sugiyama K, Obara K, Hirata H, Fukushima Y, Toda M, Fukuda T. Interferon-alpha inhibits airway eosinophilia and hyperresponsiveness in an animal asthma model [corrected]. Asia Pac Allergy 2012;2:256-63. [PMID: 23130331 DOI: 10.5415/apallergy.2012.2.4.256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
254 Berger CT, Kim AY. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012;26:863-77. [PMID: 23083820 DOI: 10.1016/j.idc.2012.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
255 Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol. 2014;11:362-371. [PMID: 24535328 DOI: 10.1038/nrgastro.2014.17] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 13.3] [Reference Citation Analysis]
256 Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E, Planas R, Ausina V, Martró E. Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One 2013;8:e72600. [PMID: 24015264 DOI: 10.1371/journal.pone.0072600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
257 Mathur P, Kottilil S, Wilson E. Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. J Clin Transl Hepatol 2018;6:431-7. [PMID: 30637222 DOI: 10.14218/JCTH.2018.00007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
258 McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32 Suppl 1:151-156. [PMID: 22212587 DOI: 10.1111/j.1478-3231.2011.02706.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 10.9] [Reference Citation Analysis]
259 Jeong SH, Jung YK, Yang JW, Park SJ, Kim JW, Kwon OS, Kim YS, Choi DJ, Kim JH. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. Clin Mol Hepatol 2012;18:360-7. [PMID: 23323251 DOI: 10.3350/cmh.2012.18.4.360] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
260 Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada. J Urban Health 2004;81:428-47. [PMID: 15273266 DOI: 10.1093/jurban/jth128] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
261 Yan Z, Fan K, Fan Y, Wang X, Mao Q, Deng G, Wang Y. Thyroid dysfunction in chinese patients with chronic hepatitis C treated with interferon alpha: incidence, long-term outcome and predictive factors. Hepat Mon 2012;12:e6390. [PMID: 23087763 DOI: 10.5812/hepatmon.6390] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
262 Qiu Q, Wang RY, Jiao X, Jin B, Sugauchi F, Grandinetti T, Alter HJ, Shih JW. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine. 2008;26:5527-5534. [PMID: 18675871 DOI: 10.1016/j.vaccine.2008.07.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
263 Numata M, Kagawa T, Kojima S, Hirose S, Nagata N, Shiraishi K, Watanabe N, Shiozawa H, Nishizaki Y, Motegi S, Takashimizu S, Kamochi J, Wasada M, Ohno T, Tei Y, Nakano A, Yamada T, Atsukawa K, Watanabe T, Mine T. Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. Hepat Res Treat 2010;2010:702748. [PMID: 21188199 DOI: 10.1155/2010/702748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
264 Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444. [PMID: 21898493 DOI: 10.1002/hep.24641].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
265 Rehan HS, Manak S, Yadav M. Supervised conventional interferon α2a in combination with ribavirin therapy is the preferred alternative for treatment of chronic hepatitis C. Indian J Pharmacol 2014;46:490-2. [PMID: 25298576 DOI: 10.4103/0253-7613.140578] [Reference Citation Analysis]
266 Xu Y, Jiang X, Zhou Y, Ma M, Wang M, Ying B. Systematic Evolution of Ligands by Exponential Enrichment Technologies and Aptamer-Based Applications: Recent Progress and Challenges in Precision Medicine of Infectious Diseases. Front Bioeng Biotechnol 2021;9:704077. [PMID: 34447741 DOI: 10.3389/fbioe.2021.704077] [Reference Citation Analysis]
267 Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7(26): 2676-2680 [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
268 Howell CD, Dowling TC, Paul M, Wahed AS, Terrault NA, Taylor M, Jeffers L, Hoofnagle JH; Virahep-C Study Group. Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2008;6:575-83. [PMID: 18407798 DOI: 10.1016/j.cgh.2008.02.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
269 Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33 Suppl 1:68-79. [PMID: 23286849 DOI: 10.1111/liv.12063] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
270 Li S, Xing X, Yang Q, Xu H, He J, Chen Z, Zhu H. The effects of hepatitis C virus core protein on the expression of miR-122 in vitro. Virol J 2013;10:98. [PMID: 23537271 DOI: 10.1186/1743-422X-10-98] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
271 Thomas E, Fried MW. Hepatitis C: current options for nonresponders to peginterferon and ribavirin. Curr Gastroenterol Rep 2008;10:53-9. [PMID: 18417043 DOI: 10.1007/s11894-008-0009-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
272 Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015; 7(24): 2543-2550 [PMID: 26523206 DOI: 10.4254/wjh.v7.i24.2543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
273 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
274 Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70:147-165. [PMID: 20108989 DOI: 10.2165/11531990-000000000-00000] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
275 D'Ambrosio R, Aghemo A. Treatment of patients with HCV related cirrhosis: many rewards with very few risks. Hepat Mon 2012;12:361-8. [PMID: 22879824 DOI: 10.5812/hepatmon.6095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
276 Colussi G, Donnini D, Brizzi RF, Maier S, Valenti L, Catena C, Cavarape A, Sechi LA, Soardo G. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study. World J Gastroenterol 2019; 25(40): 6094-6106 [PMID: 31686765 DOI: 10.3748/wjg.v25.i40.6094] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
277 De Kaita K, Wong S, Renner E, Minuk GY. Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials. Can J Gastroenterol 2006;20:87-90. [PMID: 16482233 DOI: 10.1155/2006/148962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
278 Goyal A, Hofmann WP, Hermann E, Traver S, Hissar SS, Arora N, Blum HE, Zeuzem S, Sarrazin C, Sarin SK. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med Microbiol Immunol 2007;196:11-21. [PMID: 16955308 DOI: 10.1007/s00430-006-0024-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
279 Côté P, Baril JG, Hébert MN, Klein M, Lalonde R, Poliquin M, Rouleau D, Therrien R, Vézina S, Willems B, Dion H, Junod P, Lapointe N, Lévesque D, Pinault L, Tremblay C, Trottier B, Trottier S, Tsoukas C, Piché A. Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol 2007;18:293-303. [PMID: 18923731 DOI: 10.1155/2007/631054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
280 Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol 2012; 18(8): 800-805 [PMID: 22371640 DOI: 10.3748/wjg.v18.i8.800] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 97] [Article Influence: 9.4] [Reference Citation Analysis]
281 Li B, Ji YJ, Shao Q, Zhu Z, Ji D, Li F, Chen G. Comparative efficacy and cost effectiveness of splenectomy and thrombopoietin prior to peginterferon and ribavirin therapy with compensatory cirrhosis associated with hepatitis C and thrombocytopenia. Exp Ther Med 2015;10:2180-6. [PMID: 26668613 DOI: 10.3892/etm.2015.2830] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
282 Welsch C, Schweizer S, Shimakami T, Domingues FS, Kim S, Lemon SM, Antes I. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob Agents Chemother. 2012;56:1907-1915. [PMID: 22252823 DOI: 10.1128/aac.05184-11] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 2.9] [Reference Citation Analysis]
283 Harding BN, Whitney BM, Nance RM, Ruderman SA, Crane HM, Burkholder G, Moore RD, Mathews WC, Eron JJ, Hunt PW, Volberding P, Rodriguez B, Mayer KH, Saag MS, Kitahata MM, Heckbert SR, Delaney JAC. Anemia risk factors among people living with HIV across the United States in the current treatment era: a clinical cohort study. BMC Infect Dis 2020;20:238. [PMID: 32197585 DOI: 10.1186/s12879-020-04958-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med 2019;34:794-801. [PMID: 29792020 DOI: 10.3904/kjim.2017.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
285 Sultana C, Oprişan G, Teleman MD, Dinu S, HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S. Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. World J Gastroenterol 2016; 22(37): 8406-8413 [PMID: 27729747 DOI: 10.3748/wjg.v22.i37.8406] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
286 Kumar R, Hsiang JC, Tan J, Thurairajah PH. Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report. Clin Mol Hepatol 2019;25:326-30. [PMID: 30509013 DOI: 10.3350/cmh.2018.0063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
287 Pham TN, Michalak TI. Occult persistence and lymphotropism of hepatitis C virus infection. World J Gastroenterol 2008; 14(18): 2789-2793 [PMID: 18473399 DOI: 10.3748/wjg.14.2789] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
288 Watanabe T, Joko K, Seike H, Michitaka K, Horiike N, Kisaka Y, Tanaka Y, Nakanishi S, Nakanishi K, Nonaka T, Yamauchi K, Onji M, Ohno Y, Tokumoto Y, Hirooka M, Abe M, Hiasa Y. Simeprevir with peginterferon/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients. Springerplus 2016;5:518. [PMID: 27186482 DOI: 10.1186/s40064-016-2190-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
289 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
290 Yoshida EM, Dar Santos A, Partovi N, Ford JA. Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number. Can J Gastroenterol 2006;20:519-20. [PMID: 16967572 DOI: 10.1155/2006/793589] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006;41:17-27. [PMID: 16501853 DOI: 10.1007/s00535-005-1740-7] [Cited by in Crossref: 112] [Cited by in F6Publishing: 101] [Article Influence: 7.0] [Reference Citation Analysis]
292 Ali L, Idrees M, Ali M, Hussain A, Ur Rehman I, Ali A, Iqbal SA, Kamel EH. Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines. BMC Res Notes 2014;7:247. [PMID: 24742271 DOI: 10.1186/1756-0500-7-247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
293 Zou X, Chi X, Pan Y, Du D, Sun H, Matsuda A, Li W, Kuno A, Zhang X, Narimatsu H, Niu J, Zhang Y. LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. Clin Proteomics 2014;11:44. [PMID: 25593566 DOI: 10.1186/1559-0275-11-44] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
294 Ling YM, Chen JY, Guo L, Wang CY, Tan WT, Wen Q, Zhang SD, Deng GH, Lin Y, Kwok HF. β-defensin 1 expression in HCV infected liver/liver cancer: an important role in protecting HCV progression and liver cancer development. Sci Rep 2017;7:13404. [PMID: 29042578 DOI: 10.1038/s41598-017-13332-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
295 Kogure T, Ueno Y, Fukushima K, Nagasaki F, Kondo Y, Inoue J, Matsuda Y, Kakazu E, Yamamoto T, Onodera H, Miyazaki Y, Okamoto H, Akahane T, Kobayashi T, Mano Y, Iwasaki T, Ishii M, Shimosegawa T. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan. World J Gastroenterol 2008; 14(47): 7225-7230 [PMID: 19084938 DOI: 10.3748/wjg.14.7225] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
296 Beaumont E, Roingeard P. Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Hum Vaccin Immunother. 2013;9:1112-1118. [PMID: 23406827 DOI: 10.4161/hv.23900] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
297 Chang KC, Wu YY, Hung CH, Lu SN, Lee CM, Chiu KW, Tsai MC, Tseng PL, Huang CM, Cho CL, Chen HH, Hu TH. Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy. Br J Cancer 2013;109:2481-8. [PMID: 24084770 DOI: 10.1038/bjc.2013.564] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
298 Morikawa H, Fukuda K, Kobayashi S, Fujii H, Iwai S, Enomoto M, Tamori A, Sakaguchi H, Kawada N. Real-time tissue elastography as a tool for the noninvasive assessment of liver stiffness in patients with chronic hepatitis C. J Gastroenterol. 2011;46:350-358. [PMID: 20697747 DOI: 10.1007/s00535-010-0301-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
299 Wong T, Lee SS. Hepatitis C: a review for primary care physicians. CMAJ. 2006;174:649-659. [PMID: 16505462 DOI: 10.1503/cmaj.1030034] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.1] [Reference Citation Analysis]
300 Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010;59:1401-1409. [PMID: 20675691 DOI: 10.1136/gut.2010.207423.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Wu C, Gilroy R, Taylor R, Olyaee M, Abdulkarim B, Forster J, O’Neil M, Damjanov I, Wan YJ. Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking. Hepatology. 2011;54:1966-1974. [PMID: 21898497 DOI: 10.1002/hep.24645] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
302 Kraus MR, Schäfer A, Csef H, Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005; 11(12): 1769-1774 [PMID: 15793861 DOI: 10.3748/wjg.v11.i12.1769] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
303 Marrero R, Schiff E. Viral hepatitis. Curr Opin Gastroenterol 2002;18:330-3. [PMID: 17033303 DOI: 10.1097/00001574-200205000-00006] [Reference Citation Analysis]
304 Money DM. Antiviral and antiretroviral use in pregnancy. Obstet Gynecol Clin North Am 2003;30:731-49, vii. [PMID: 14719848 DOI: 10.1016/s0889-8545(03)00089-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
305 Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon. 2011;11:968-974. [PMID: 22368680 DOI: 10.5812/kowsar.1735143x.4223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C. Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. J Clin Virol 2014;59:148-55. [PMID: 24462470 DOI: 10.1016/j.jcv.2013.12.011] [Reference Citation Analysis]
307 Sarrazin C, Gärtner BC, Sizmann D, Babiel R, Mihm U, Hofmann WP, von Wagner M, Zeuzem S. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 2006;44:729-37. [PMID: 16517847 DOI: 10.1128/JCM.44.3.729-737.2006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
308 Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I. Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One 2009;4:e4319. [PMID: 19183807 DOI: 10.1371/journal.pone.0004319] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
309 Rafique S, Idrees M, Ali A, Sahibzada KI, Iqbal M. Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection. Mol Biol Rep 2014;41:3813-9. [PMID: 24549717 DOI: 10.1007/s11033-014-3247-x] [Reference Citation Analysis]
310 Fu QX, Wang LC, Jia SZ, Gao B, Zhou Y, Du J, Wang YL, Wang XH, Peng JC, Zhan LS. Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model. World J Gastroenterol 2010; 16(44): 5582-5587 [PMID: 21105190 DOI: 10.3748/wjg.v16.i44.5582] [Reference Citation Analysis]
311 Chen LZ, Rose P, Mao Y, Yong CL, St George R, Huang F, Latli B, Mandarino D, Li Y. Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother 2014;58:2369-76. [PMID: 24514093 DOI: 10.1128/AAC.02156-13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
312 Poonsapaya JM, Einodshofer M, Kirkham HS, Glover P, DuChane J. New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison. Cost Eff Resour Alloc 2015;13:17. [PMID: 26445564 DOI: 10.1186/s12962-015-0043-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
313 Vecchio F, Messina G, Giovenzana A, Petrelli A. New Evidence of Exocrine Pancreatopathy in Pre-symptomatic and Symptomatic Type 1 Diabetes. Curr Diab Rep 2019;19:92. [PMID: 31471779 DOI: 10.1007/s11892-019-1223-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
314 Grandi T, da Silva CM, Amaral KM, Picon PD, Costi C, da Fré NN, Fiegenbaum M, Niel C, Rossetti ML. Response to treatment in Brazilian patients with chronic hepatitis C is associated with a single-nucleotide polymorphism near the interleukin-28B gene. Mem Inst Oswaldo Cruz 2013;108:48-53. [PMID: 23440114 DOI: 10.1590/s0074-02762013000100008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
315 Dill MT, Makowska Z, Trincucci G, Gruber AJ, Vogt JE, Filipowicz M, Calabrese D, Krol I, Lau DT, Terracciano L, van Nimwegen E, Roth V, Heim MH. Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation. J Clin Invest 2014;124:1568-81. [PMID: 24569457 DOI: 10.1172/JCI70408] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
316 Jonsson JR, Purdie DM, Clouston AD, Powell EE. Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. Mol Diagn Ther 2008;12:209-18. [PMID: 18652517 DOI: 10.1007/BF03256286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
317 Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002;76:12735-46. [PMID: 12438599 DOI: 10.1128/jvi.76.24.12735-12746.2002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
318 Russo MW, Fried MW. Guidelines for stopping therapy in chronic hepatitis C. Curr Gastroenterol Rep. 2004;6:17-21. [PMID: 14720449 DOI: 10.1007/s11894-004-0021-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
319 Sypsa V, Hadjipaschali E, Hatzakis A. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees. Eur J Epidemiol 2001;17:721-8. [PMID: 12086089 DOI: 10.1023/a:1015671627577] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
320 Khatun M, Ray RB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:E1249. [PMID: 31615075 DOI: 10.3390/cells8101249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
321 Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 2008;6:66. [PMID: 18986530 DOI: 10.1186/1479-5876-6-66] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
322 Eskander EF, Abd-Rabou AA, Yahya SM, El Sherbini A, Mohamed MS, Shaker OG. Correlation and multiple regression analyses of pituitary growth hormone and hepatic activities in hepatitis C infection and interferon response. Indian J Clin Biochem 2013;28:348-57. [PMID: 24426236 DOI: 10.1007/s12291-013-0309-0] [Reference Citation Analysis]
323 Thong VD, Akkarathamrongsin S, Poovorawan K, Tangkijvanich P, Poovorawan Y. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication. World J Gastroenterol 2014; 20(11): 2927-2940 [PMID: 24659883 DOI: 10.3748/wjg.v20.i11.2927] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
324 Hong W, Lang Y, Li T, Zeng Z, Song Y, Wu Y, Li W, Cao Z. A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro. J Biol Chem 2015;290:23254-63. [PMID: 26251517 DOI: 10.1074/jbc.M115.662452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
325 Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol 2014;4:85-6. [PMID: 25755543 DOI: 10.1016/j.jceh.2014.06.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
326 Vitor S, Marinho RT, Gíria J, Velosa J. An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes 2016;9:62. [PMID: 26843372 DOI: 10.1186/s13104-016-1879-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
327 Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, Tian Y, Hung M, Fung W, Vivian RW, Trenkle J, Taylor J, Bjornson K, Bondy S, Liu X, Link J, Neyts J, Sakowicz R, Zhong W, Tang H, Schmitz U. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 2012;7:e39163. [PMID: 22720059 DOI: 10.1371/journal.pone.0039163] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
328 Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J Gastroenterol 2007; 13(8): 1195-1203 [PMID: 17451199 DOI: 10.3748/wjg.v13.i8.1195] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
329 Zhou Y, Bartels DJ, Hanzelka BL, Müh U, Wei Y, Chu HM, Tigges AM, Brennan DL, Rao BG, Swenson L, Kwong AD, Lin C. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2008;52:110-20. [PMID: 17938182 DOI: 10.1128/AAC.00863-07] [Cited by in Crossref: 77] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
330 Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. Front Pharmacol 2020;11:550205. [PMID: 32982753 DOI: 10.3389/fphar.2020.550205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
331 Seidenberg A, Rosemann T, Senn O. Patients receiving opioid maintenance treatment in primary care: successful chronic hepatitis C care in a real world setting. BMC Infect Dis. 2013;13:9. [PMID: 23298178 DOI: 10.1186/1471-2334-13-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
332 Herlihy KJ, Graham JP, Kumpf R, Patick AK, Duggal R, Shi ST. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob Agents Chemother 2008;52:3523-31. [PMID: 18694956 DOI: 10.1128/AAC.00533-08] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
333 Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk ST, Köse Ş, Korkmaz F, Kuruüzüm Z, Tuna N, Taheri S, Sayan M, Demir NA, Sümer Ş, Altınok ES. Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Med J 2015;32:266-72. [PMID: 26185714 DOI: 10.5152/balkanmedj.2015.15366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
334 Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18. [PMID: 18184025 DOI: 10.2165/00002512-200825010-00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
335 Mechie NC, Röver C, Cameron S, Amanzada A. Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis. World J Hepatol 2014; 6(10): 759-765 [PMID: 25349647 DOI: 10.4254/wjh.v6.i10.759] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
336 Shudo E, Ribeiro RM, Perelson AS. Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol 2009;5:321-32. [PMID: 19331594 DOI: 10.1517/17425250902787616] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
337 Khalsa JH, Treisman G, McCance-Katz E, Tedaldi E. Medical consequences of drug abuse and co-occurring infections: research at the National Institute on Drug Abuse. Subst Abus 2008;29:5-16. [PMID: 19042203 DOI: 10.1080/08897070802218661] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
338 Grassi A, Ballardini G. Hepatitis C in injection drug users: It is time to treat. World J Gastroenterol 2017; 23(20): 3569-3571 [PMID: 28611509 DOI: 10.3748/wjg.v23.i20.3569] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
339 Pellicano R, Craxì A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon β-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11(29): 4484-4489 [PMID: 16052676 DOI: 10.3748/wjg.v11.i29.4484] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
340 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2021. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Reference Citation Analysis]
341 Baloch K, Chen L, Memon AA, Dexter L, Irving W, Ilyas M, Thomson BJ. Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Antivir Chem Chemother 2017;25:2-10. [PMID: 28417642 DOI: 10.1177/2040206616686894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
342 Wu JZ, Larson G, Hong Z. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin. Antimicrob Agents Chemother 2004;48:4006-8. [PMID: 15388466 DOI: 10.1128/AAC.48.10.4006-4008.2004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
343 Shalev I, Selzner N, Helmy A, Foerster K, Adeyi OA, Grant DR, Levy G. The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. Rambam Maimonides Med J 2010;1:e0004. [PMID: 23908776 DOI: 10.5041/RMMJ.10004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
344 Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 2010;17:139-47. [PMID: 19674282 DOI: 10.1111/j.1365-2893.2009.01157.x] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
345 Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int. 2012;109:352-358. [PMID: 22675406 DOI: 10.3238/arztebl.2012.0352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
346 Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, Jiang WR, Rajyaguru S, Tavares G, Oshiro C, Hendricks T, Klumpp K, Symons J, Browner MF, Cammack N, Nájera I. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80:6146-54. [PMID: 16731953 DOI: 10.1128/JVI.02628-05] [Cited by in Crossref: 106] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
347 Milwid JM, Elman JS, Li M, Shen K, Manrai A, Gabow A, Yarmush J, Jiao Y, Fletcher A, Lee J, Cima MJ, Yarmush ML, Parekkadan B. Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther 2014;22:999-1007. [PMID: 24496384 DOI: 10.1038/mt.2014.17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
348 Lim JK, Wooten D, Siegel R, Cheung RC. Amantadine in treatment of chronic hepatitis C virus infection? J Viral Hepat 2005;12:445-55. [PMID: 16108758 DOI: 10.1111/j.1365-2893.2005.00622.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
349 Verma V, Shen D, Sieving PC, Chan CC. The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol 2008;53:312-31. [PMID: 18572051 DOI: 10.1016/j.survophthal.2008.04.008] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
350 Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, Chiu CF, Lin ZY, Chen SC, Hsieh MY. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553-559. [PMID: 16956917 DOI: 10.1136/gut.2006.102558] [Cited by in Crossref: 218] [Cited by in F6Publishing: 198] [Article Influence: 13.6] [Reference Citation Analysis]
351 Ding Y, Lou J, Chen H, Li X, Wu M, Li C, Liu J, Liu C, Li Q, Zhang H, Niu J. Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection. Br J Clin Pharmacol 2017;83:1056-71. [PMID: 27862178 DOI: 10.1111/bcp.13184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
352 Dabbouseh NM, Jensen DM. Future therapies for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:268-76. [PMID: 23419289 DOI: 10.1038/nrgastro.2013.17] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
353 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in Crossref: 205] [Cited by in F6Publishing: 199] [Article Influence: 22.8] [Reference Citation Analysis]
354 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013;19:850-8. [PMID: 23836235 DOI: 10.1038/nm.3184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
355 Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME. Current and emerging antiviral treatments for hepatitis C infection. Br J Clin Pharmacol 2013;75:931-43. [PMID: 22882367 DOI: 10.1111/j.1365-2125.2012.04419.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
356 Lalezari J, Asmuth D, Casiró A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bólyai J, Mayers D. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2012;56:6372-8. [PMID: 23070151 DOI: 10.1128/AAC.01521-12] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
357 Wu P, Wang W, Duan W, Li Y, Hou X. Comprehensive Analysis of the CDPK-SnRK Superfamily Genes in Chinese Cabbage and Its Evolutionary Implications in Plants. Front Plant Sci 2017;8:162. [PMID: 28239387 DOI: 10.3389/fpls.2017.00162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
358 Nagao Y, Kawaguchi T, Ide T, Sata M. Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virol J 2012;9:282. [PMID: 23173649 DOI: 10.1186/1743-422X-9-282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
359 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
360 Mechie NC, Goralzcyk AD, Reinhardt L, Mihm S, Amanzada A. Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Res Notes 2015;8:260. [PMID: 26109044 DOI: 10.1186/s13104-015-1248-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
361 D'Souza R, Foster GR. Diagnosis and treatment of hepatitis C. J R Soc Med 2004;97:223-5. [PMID: 15121811 DOI: 10.1258/jrsm.97.5.223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
362 Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, Mita E, Ito T, Nagase T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 2011;46:944-52. [PMID: 21552988 DOI: 10.1007/s00535-011-0403-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
363 Arain A, Robaeys G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. World J Gastroenterol 2014; 20(36): 12722-12733 [PMID: 25278674 DOI: 10.3748/wjg.v20.i36.12722] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
364 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
365 Jou JH, Sulkowski MS, Noviello S, Long J, Pedicone LD, McHutchison JG, Muir AJ. Analysis of site performance in academic-based and community-based centers in the IDEAL Study. J Clin Gastroenterol 2013;47:e91-5. [PMID: 23787248 DOI: 10.1097/MCG.0b013e318294baa4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
366 Wei L, Shang J, Ma Y, Xu X, Huang Y, Guan Y, Duan Z, Zhang W, Gao Z, Zhang M, Li J, Jia J, Yang Y, Wen X, Wang M, Jia Z, Ning B, Chen Y, Qi Y, Du J, Jiang J, Tong L, Xie Y, Wu JJ. Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C. J Clin Transl Hepatol 2019;7:221-5. [PMID: 31608213 DOI: 10.14218/JCTH.2019.00018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
367 Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, Sacchi P, Gatti M, Dossena L, Baldanti F. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol J 2012;9:245. [PMID: 23095680 DOI: 10.1186/1743-422X-9-245] [Cited by in Crossref: 53] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
368 Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23:47-63. [PMID: 21326720 DOI: 10.1055/s-2006-939841] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 8.9] [Reference Citation Analysis]
369 Murdaca G, Contini P, Cagnati P, Marenco S, Pieri G, Lantieri F, Picciotto A, Puppo F. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy. Clin Exp Med 2017;17:93-100. [PMID: 26567007 DOI: 10.1007/s10238-015-0399-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
370 Fischer J, Böhm S, Müller T, Witt H, Sarrazin C, Susser S, Migaud P, Schott E, Stewart G, Brodzinski A, Fülöp B, van Bömmel F, George J, Berg T. Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection. PLoS One 2013;8:e77530. [PMID: 24204859 DOI: 10.1371/journal.pone.0077530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
371 Iwasaki Y, Shiratori Y, Hige S, Nishiguchi S, Takagi H, Onji M, Yoshida H, Izumi N, Kohgo Y, Yamamoto K, Sato N, Shibuya A, Saito H, Sata M, Suzuki K, Kaneko S, Moriyama M, Omata M. A randomized trial of 24 versus 48 weeks of peginterferon α-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multicenter national study in Japan. Hepatol Int 2009;3:468-79. [PMID: 19669250 DOI: 10.1007/s12072-009-9134-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
372 Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis. 2012;12:357. [PMID: 23245594 DOI: 10.1186/1471-2334-12-357] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
373 Mirian M, Khanahmad H, Darzi L, Salehi M, Sadeghi-Aliabadi H. Oligonucleotide aptamers: potential novel molecules against viral hepatitis. Res Pharm Sci 2017;12:88-98. [PMID: 28515761 DOI: 10.4103/1735-5362.202447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
374 Niederau C, Hüppe D, Zehnter E, Möller B, Heyne R, Christensen S, Pfaff R, Theilmeier A, Alshuth U, Mauss S. Chronic hepatitis C: Treat or wait? Medical decision making in clinical practice. World J Gastroenterol 2012; 18(12): 1339-1347 [PMID: 22493547 DOI: 10.3748/wjg.v18.i12.1339] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
375 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364. [PMID: 23383326 DOI: 10.1371/journal.pone.0055364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
376 Pedersen J, Jensen TB, Carlsen TH, Schønning K, Christensen PB, Laursen AL, Krarup H, Bukh J, Weis N. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. PLoS One 2013;8:e62674. [PMID: 23667506 DOI: 10.1371/journal.pone.0062674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
377 Perales C, Quer J, Gregori J, Esteban JI, Domingo E. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications. Viruses. 2015;7:5746-5766. [PMID: 26561827 DOI: 10.3390/v7112902] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
378 Hochstatter KR, Stockman LJ, Holzmacher R, Greer J, Seal DW, Taylor QA, Gill EK, Westergaard RP. The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care. Health Justice 2017;5:10. [PMID: 29086078 DOI: 10.1186/s40352-017-0055-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
379 Loustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World J Hepatol 2016; 8(2): 123-130 [PMID: 26807208 DOI: 10.4254/wjh.v8.i2.123] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
380 Walewski JL, Gutierrez JA, Branch-Elliman W, Stump DD, Keller TR, Rodriguez A, Benson G, Branch AD. Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA 2002;8:557-71. [PMID: 12022223 DOI: 10.1017/s1355838202029023] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
381 Pearlman BL. The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. Curr Gastroenterol Rep 2011;13:78-86. [PMID: 21080244 DOI: 10.1007/s11894-010-0161-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
382 Gomes C, Ginzberg D, Wong RJ. Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience. J Transl Int Med 2020;8:261-7. [PMID: 33511053 DOI: 10.2478/jtim-2020-0039] [Reference Citation Analysis]
383 Al-Judaibi B. The new era of hepatitis C virus therapy. Saudi J Gastroenterol 2015;21:345-54. [PMID: 26655128 DOI: 10.4103/1319-3767.170947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
384 Chen EY, Lee WM, Hynan LS, Singal AG. A survey of hepatitis C treatment clinical practice patterns using the newly approved protease inhibitors. J Clin Gastroenterol 2013;47:800-6. [PMID: 23470640 DOI: 10.1097/MCG.0b013e31828a37c0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
385 Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005;79:6023-6034. [PMID: 15857988 DOI: 10.1128/jvi.79.10.6023-6034.2005] [Cited by in Crossref: 201] [Cited by in F6Publishing: 97] [Article Influence: 11.8] [Reference Citation Analysis]
386 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
387 Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. Factors that influence an HIV coinfected patient’s decision to start hepatitis C treatment. AIDS Patient Care STDS. 2009;23:993-999. [PMID: 19929229 DOI: 10.1089/apc.2009.0153] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
388 Ijaz B, Ahmad W, Javed FT, Gull S, Sarwar MT, Kausar H, Asad S, Jahan S, Khaliq S, Shahid I. Association of laboratory parameters with viral factors in patients with hepatitis C. Virol J. 2011;8:361. [PMID: 21777434 DOI: 10.1186/1743-422x-8-361] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
389 Ocker M, Ganslmayer M, Zopf S, Gahr S, Janson C, Hahn EG, Herold C. Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. World J Gastroenterol 2005; 11(35): 5521-5524 [PMID: 16222747 DOI: 10.3748/wjg.v11.i35.5521] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
390 Dahari H, Ribeiro RM, Rice CM, Perelson AS. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 2007;81:750-60. [PMID: 17035310 DOI: 10.1128/JVI.01304-06] [Cited by in Crossref: 79] [Cited by in F6Publishing: 52] [Article Influence: 4.9] [Reference Citation Analysis]
391 Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE; Virahep-C Study Group. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS One 2008;3:e2123. [PMID: 18463735 DOI: 10.1371/journal.pone.0002123] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
392 Kayali Z, Labrecque DR, Schmidt WN. Treatment of hepatitis C cryoglobulinemia: mission and challenges. Curr Treat Options Gastroenterol 2006;9:497-507. [PMID: 17081483 DOI: 10.1007/s11938-006-0006-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
393 Gibbert K, Schlaak JF, Yang D, Dittmer U. IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol. 2013;168:1048-1058. [PMID: 23072338 DOI: 10.1111/bph.12010] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 10.1] [Reference Citation Analysis]
394 Nudo CG, Wong P, Hilzenrat N, Deschênes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. Can J Gastroenterol 2006;20:589-92. [PMID: 17001400 DOI: 10.1155/2006/357259] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
395 Cai Q, Zhang X, Lin C, Shao X, Guan Y, Deng H, Wei M, Huang M, Ren Z, Lu L, Mei Y, Xu M, Zhu J, Shi H, Lin G, Liu Y, Hu F, Luo Q, Lan Y, Guo F, Zhao Z, Gao Z. 24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. PLoS One 2015;10:e0140853. [PMID: 26509605 DOI: 10.1371/journal.pone.0140853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
396 Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, Yamada G, Yokosuka O, Shiratori Y. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425-430. [PMID: 14960528 DOI: 10.1136/gut.2003.030353] [Cited by in Crossref: 119] [Cited by in F6Publishing: 109] [Article Influence: 6.6] [Reference Citation Analysis]
397 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res. 2016;2016:6837241. [PMID: 27069936 DOI: 10.1155/2016/6837241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
398 Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS One 2012;7:e52158. [PMID: 23284915 DOI: 10.1371/journal.pone.0052158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
399 Wang XX, Luo BF, Jiang HJ, Cong X, Jin Q, Ma DL, Wei L, Feng B. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. World J Gastroenterol 2018; 24(40): 4554-4564 [PMID: 30386105 DOI: 10.3748/wjg.v24.i40.4554] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
400 Vargas HE, Rakela J. Impact of hepatitis B and hepatitis C on solid organ transplantation: . Current Opinion in Organ Transplantation 2002;7:325-31. [DOI: 10.1097/00075200-200212000-00005] [Reference Citation Analysis]
401 Friedrich-Rust M, Zeuzem S, Sarrazin C. Current therapy for hepatitis C. Int J Colorectal Dis. 2007;22:341-349. [PMID: 16175369 DOI: 10.1007/s00384-005-0038-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
402 Zhou XM, Chan PK, Tam JS. Mutations around interferon sensitivity-determining region: A pilot resistance report of hepatitis C virus 1b in a Hong Kong population. World J Gastroenterol 2011; 17(48): 5317-5323 [PMID: 22219602 DOI: 10.3748/wjg.v17.i48.5317] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
403 Mehta SH, Kirk GD, Astemborski J, Sulkowski MS, Afdhal NH, Thomas DL. Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther 2012;17:813-21. [PMID: 22418880 DOI: 10.3851/IMP2085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
404 Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009;29:4-14. [PMID: 19139619 DOI: 10.4103/0256-4947.51816] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
405 Larrey D, Ripault MP, Pageaux GP. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adherence 2014;8:763-73. [PMID: 24920888 DOI: 10.2147/PPA.S30339] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
406 De Clercq E. Ebola virus (EBOV) infection: Therapeutic strategies. Biochem Pharmacol 2015;93:1-10. [PMID: 25481298 DOI: 10.1016/j.bcp.2014.11.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
407 Murata K, Sugiyama M, Kimura T, Yoshio S, Kanto T, Kirikae I, Saito H, Aoki Y, Hiramine S, Matsui T. Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients. J Gastroenterol. 2014;49:126-137. [PMID: 23591768 DOI: 10.1007/s00535-013-0814-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
408 Hakim S, Kazmi S, Bagasra O. Seroprevalence of hepatitis B and C genotypes among young apparently healthy females of karachi-pakistan. Libyan J Med. 2008;3:66-70. [PMID: 21499460 DOI: 10.4176/071123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
409 Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol. 2012;47:834-844. [PMID: 22350701 DOI: 10.1007/s00535-012-0550-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
410 Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bólyai J, Mayers D. Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 2011;55:76-81. [PMID: 21060109 DOI: 10.1128/AAC.01101-10] [Cited by in Crossref: 49] [Cited by in F6Publishing: 16] [Article Influence: 4.1] [Reference Citation Analysis]
411 Hetta HF, Mehta MJ, Shata MTM. Gut immune response in the presence of hepatitis C virus infection. World J Immunol 2014; 4(2): 52-62 [DOI: 10.5411/wji.v4.i2.52] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
412 Jang JY, Chung RT. Chronic hepatitis C. Gut Liver. 2011;5:117-132. [PMID: 21814590 DOI: 10.5009/gnl.2011.5.2.117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
413 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013;21:625-33. [PMID: 24238778 DOI: 10.1016/j.tim.2013.09.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
414 Chua BY, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J, Jackson DC. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008;26:4866-75. [PMID: 18455278 DOI: 10.1016/j.vaccine.2008.03.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
415 Dalgard O, Mangia A. Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. Drugs 2006;66:1807-15. [PMID: 17040112 DOI: 10.2165/00003495-200666140-00003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
416 Luna JM, Saeed M, Rice CM. Taming a beast: lessons from the domestication of hepatitis C virus. Curr Opin Virol 2019;35:27-34. [PMID: 30875640 DOI: 10.1016/j.coviro.2019.02.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
417 d'Avigdor WMH, Budzinska MA, Lee M, Lam R, Kench J, Stapelberg M, McLennan SV, Farrell G, George J, McCaughan GW, Tu T, Shackel NA. Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. Sci Rep 2019;9:10596. [PMID: 31332246 DOI: 10.1038/s41598-019-46664-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
418 Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int. 2010;4:723-731. [PMID: 21286343 DOI: 10.1007/s12072-010-9207-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
419 Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005;54:1014-20. [PMID: 15951552 DOI: 10.1136/gut.2004.057893] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
420 Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011;56:2221-2226. [PMID: 21643737 DOI: 10.1007/s10620-011-1765-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
421 Njiomegnie GF, Read SA, Fewings N, George J, McKay F, Ahlenstiel G. Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection. J Clin Med. 2020;9. [PMID: 32268490 DOI: 10.3390/jcm9041030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
422 Fuhrmann V, Kramer L, Bauer E, Laferl H, Tucek G, Dekan G, Schenk P. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection. Dig Dis Sci 2004;49:1966-70. [PMID: 15628735 DOI: 10.1007/s10620-004-9602-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
423 Yao Y, Yue M, Zang F, Liu M, Fan H, Zhuo L, Wu J, Xia X, Feng Y, Huang P, Yu R. Genetic variants in chemokine CC subfamily genes influence hepatitis C virus viral clearance. J Hum Genet 2018;63:831-9. [PMID: 29703961 DOI: 10.1038/s10038-018-0452-9] [Reference Citation Analysis]
424 Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA. 2010;107:5995-5999. [PMID: 20231449 DOI: 10.1073/pnas.0914009107] [Cited by in Crossref: 177] [Cited by in F6Publishing: 163] [Article Influence: 14.8] [Reference Citation Analysis]
425 Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM. Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol 2012;26:205-10. [PMID: 22506260 DOI: 10.1155/2012/751057] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
426 Schlaak JF, Trippler M, Hoyo-Becerra C, Erim Y, Kis B, Wang B, Scherbaum N, Gerken G. Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One 2012;7:e38668. [PMID: 22701688 DOI: 10.1371/journal.pone.0038668] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
427 Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut. 2007;56:385-389. [PMID: 17005764 DOI: 10.1136/gut.2006.099150] [Cited by in Crossref: 113] [Cited by in F6Publishing: 118] [Article Influence: 7.1] [Reference Citation Analysis]
428 Ishii K, Shinohara M, Kogame M, Shiratori M, Higami K, Kanayama K, Shiozawa K, Wakui N, Nagai H, Watanabe M, Sumino Y. Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. Hepatol Int 2012;6:468-74. [PMID: 21818686 DOI: 10.1007/s12072-011-9305-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
429 Müller C. Chronic Hepatitis B and C--current treatment and future therapeutic prospects. Wien Med Wochenschr. 2006;156:391-396. [PMID: 16937041 DOI: 10.1007/s10354-006-0314-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
430 Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62. [PMID: 29770005 DOI: 10.14745/ccdr.v42i03a02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
431 Elsharkawy AM, Miller C, Hearn A, Buerstedde G, Price A, McPherson S. Improving access to treatment for patients with chronic hepatitis C through outreach. Frontline Gastroenterol 2013;4:125-9. [PMID: 28839713 DOI: 10.1136/flgastro-2012-100282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
432 Scott JD, Wald A, Kitahata M, Krantz E, Drolette L, Corey L, Wang CC. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS 2009;23:925-9. [PMID: 19827950 DOI: 10.1089/apc.2009.0099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
433 Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother. 2012;23:1-12. [PMID: 22592135 DOI: 10.3851/imp2125] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
434 Bauer L, Lyoo H, van der Schaar HM, Strating JR, van Kuppeveld FJ. Direct-acting antivirals and host-targeting strategies to combat enterovirus infections. Curr Opin Virol 2017;24:1-8. [PMID: 28411509 DOI: 10.1016/j.coviro.2017.03.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
435 Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109. [PMID: 19749757 DOI: 10.1038/ng.449] [Cited by in Crossref: 1664] [Cited by in F6Publishing: 1593] [Article Influence: 128.0] [Reference Citation Analysis]
436 Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616 [PMID: 26140081 DOI: 10.4254/wjh.v7.i12.1606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
437 Diago M, Castellano G, García-Samaniego J, Pérez C, Fernández I, Romero M, Iacono OL, García-Monzón C. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006;55:374-379. [PMID: 16150856 DOI: 10.1136/gut.2005.074062] [Cited by in Crossref: 112] [Cited by in F6Publishing: 110] [Article Influence: 6.6] [Reference Citation Analysis]
438 Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG. Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther. 2010;31:1018-1027. [PMID: 20163377 DOI: 10.1111/j.1365-2036.2010.04263.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
439 Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138:671-681, 681.e1-2. [PMID: 19782083 DOI: 10.1053/j.gastro.2009.09.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 5.7] [Reference Citation Analysis]
440 Furusyo N, Katoh M, Tanabe Y, Kajiwara E, Maruyama T, Shimono J, Sakai H, Nakamuta M, Nomura H, Masumoto A, Shimoda S, Takahashi K, Azuma K, Hayashi J, Group KULDS. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Disease Study Group. World J Gastroenterol 2006; 12(5): 784-790 [PMID: 16521196 DOI: 10.3748/wjg.v12.i5.784] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
441 Elbeik T, Surtihadi J, Destree M, Gorlin J, Holodniy M, Jortani SA, Kuramoto K, Ng V, Valdes R, Valsamakis A. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol. 2004;42:563-569. [PMID: 14766817 DOI: 10.1128/jcm.42.2.563-569.2004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
442 Jun DW, Tak WY, Bae SH, Lee YJ. Recent trends in the treatment of chronic hepatitis C. Korean J Hepatol 2012;18:22-8. [PMID: 22511899 DOI: 10.3350/kjhep.2012.18.1.22] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
443 Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE 4th. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother 2014;58:647-53. [PMID: 23939899 DOI: 10.1128/AAC.00487-13] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
444 Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Moriya K, Shiina S, Koike K. Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) 2015;94:e901. [PMID: 26061310 DOI: 10.1097/MD.0000000000000901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
445 Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L. Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2014;14:465. [PMID: 25164700 DOI: 10.1186/1471-2334-14-465] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
446 Tuaillon E, Mondain AM, Ottomani L, Roudière L, Perney P, Picot MC, Séguret F, Blanc F, Larrey D, Van de Perre P, Ducos J. Impact of hepatitis C virus (HCV) genotypes on quantification of HCV RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott HCV realtime assay [corrected] and VERSANT HCV RNA assay. J Clin Microbiol 2007;45:3077-81. [PMID: 17581929 DOI: 10.1128/JCM.00111-07] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
447 Palanisamy N, Lennerstrand J. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. Interdiscip Sci 2018;10:143-56. [PMID: 27311576 DOI: 10.1007/s12539-016-0177-4] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
448 Ratziu V, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. Curr Gastroenterol Rep. 2004;6:22-29. [PMID: 14720450 DOI: 10.1007/s11894-004-0022-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
449 Saeed N, Gurakar A. Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. Euroasian J Hepatogastroenterol 2016;6:35-42. [PMID: 29201722 DOI: 10.5005/jp-journals-10018-1163] [Reference Citation Analysis]
450 Horscroft N, Bellows D, Ansari I, Lai VC, Dempsey S, Liang D, Donis R, Zhong W, Hong Z. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. J Virol. 2005;79:2788-2796. [PMID: 15708997 DOI: 10.1128/JVI.79.5.2788-2796.2005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
451 Duncan I, Curtis R, Reyes JC, Abadie R, Khan B, Dombrowski K. Hepatitis C serosorting among people who inject drugs in rural Puerto Rico. Prev Med Rep 2017;6:38-43. [PMID: 28271018 DOI: 10.1016/j.pmedr.2017.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
452 Crisan D, Grigorescu MD, Radu C, Suciu A, Grigorescu M. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response. Indian J Med Res 2017;145:543-50. [PMID: 28862188 DOI: 10.4103/ijmr.IJMR_1410_14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Rossi SJ, Wright TL. New developments in the treatment of hepatitis C. Gut 2003;52:756-7. [PMID: 12692065 DOI: 10.1136/gut.52.5.756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
454 Ozeki I, Akaike J, Karino Y, Arakawa T, Kuwata Y, Ohmura T, Sato T, Kamiya N, Yamada I, Chayama K, Kumada H, Toyota J. Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. J Gastroenterol 2011;46:929-37. [PMID: 21556829 DOI: 10.1007/s00535-011-0411-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
455 Roe B, Kensicki E, Mohney R, Hall WW. Metabolomic profile of hepatitis C virus-infected hepatocytes. PLoS One. 2011;6:e23641. [PMID: 21853158 DOI: 10.1371/journal.pone.0023641] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 5.4] [Reference Citation Analysis]
456 Fazili J, Mallonee S, Tierney WM, Bader TF, Sachdev AK, Bird PC, Schmidt RD, Mesiya SA, Lackey CL. Outcome of a hepatitis C outbreak among patients in a pain management clinic. Dig Dis Sci 2010;55:1738-43. [PMID: 20411419 DOI: 10.1007/s10620-010-1228-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
457 Liu D, Ndongwe TP, Puray-Chavez M, Casey MC, Izumi T, Pathak VK, Tedbury PR, Sarafianos SG. Effect of P-body component Mov10 on HCV virus production and infectivity. FASEB J 2020;34:9433-49. [PMID: 32496609 DOI: 10.1096/fj.201800641R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
458 Kuwashiro T, Iwane S, Jinghe X, Matsuhashi S, Eguchi Y, Anzai K, Fujimoto K, Mizuta T, Sakamoto N, Ikeda M, Kato N, Ozaki I. Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix. Int J Mol Med 2018;42:957-65. [PMID: 29786754 DOI: 10.3892/ijmm.2018.3693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
459 Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63 Suppl 2:ii18-ii24. [PMID: 15479865 DOI: 10.1136/ard.2004.028209] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 5.6] [Reference Citation Analysis]
460 Gupta S, Singh R. Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS One 2012;7:e41209. [PMID: 22911761 DOI: 10.1371/journal.pone.0041209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
461 Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009;43:686-91. [PMID: 19295448 DOI: 10.1097/MCG.0b013e31818dd94c] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
462 Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health 2012;102:e101-6. [PMID: 22813094 DOI: 10.2105/AJPH.2011.300488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
463 Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, Wakita T, Kato N, Shimotohno K. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol. 2006;80:4510-4520. [PMID: 16611911 DOI: 10.1128/jvi.80.9.4510-4520.2006] [Cited by in Crossref: 120] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
464 Zhao S, Liu E, Wei K, Wang Y, Li Y, Huang B, Chen Y, Yang P. Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C. Eur J Clin Microbiol Infect Dis 2011;30:51-7. [PMID: 20827497 DOI: 10.1007/s10096-010-1051-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
465 Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019;43:101300. [PMID: 31771760 DOI: 10.1016/j.smim.2019.101300] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 30.5] [Reference Citation Analysis]
466 Manns MP, von Hahn T. Novel therapies for hepatitis C — one pill fits all? Nat Rev Drug Discov 2013;12:595-610. [DOI: 10.1038/nrd4050] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 15.6] [Reference Citation Analysis]
467 Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012;205:763-71. [PMID: 22293431 DOI: 10.1093/infdis/jir835] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 11.1] [Reference Citation Analysis]
468 Shepherd SJ, Abdelrahman T, MacLean AR, Thomson EC, Aitken C, Gunson RN. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort. J Clin Virol 2015;65:50-3. [PMID: 25766988 DOI: 10.1016/j.jcv.2015.02.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
469 Davison SM, Kelly DA. Management strategies for hepatitis C virus infection in children. Paediatr Drugs. 2008;10:357-365. [PMID: 18998746 DOI: 10.2165/0148581-200810060-00003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
470 Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310. [PMID: 26842909 DOI: 10.1038/srep20310] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
471 Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007;45:2426-33. [PMID: 17537941 DOI: 10.1128/JCM.02448-06] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
472 Marascio N, Pavia G, Strazzulla A, Dierckx T, Cuypers L, Vrancken B, Barreca GS, Mirante T, Malanga D, Oliveira DM, Vandamme AM, Torti C, Liberto MC, Focà A; The SINERGIE-UMG Study Group. Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients. Int J Mol Sci 2016;17:E1416. [PMID: 27618896 DOI: 10.3390/ijms17091416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
473 Horwitz R, Brener L, Treloar C. Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand. Int J Integr Care 2012;12:e229. [PMID: 23593067 DOI: 10.5334/ijic.819] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
474 Mimura I, Ishibashi Y, Tateishi R, Kaname S, Fujita T. Pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C. NDT Plus 2008;1:233-5. [PMID: 25983890 DOI: 10.1093/ndtplus/sfn069] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
475 Mascheretti S, Hinrichsen H, Ross S, Buggisch P, Hampe J, Foelsch UR, Schreiber S. Genetic variants in the CCR gene cluster and spontaneous viral elimination in hepatitis C-infected patients. Clin Exp Immunol. 2004;136:328-333. [PMID: 15086398 DOI: 10.1111/j.1365-2249.2004.02444.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
476 Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One. 2011;6:e16464. [PMID: 21297992 DOI: 10.1371/journal.pone.0016464] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
477 Lara J, Xia G, Purdy M, Khudyakov Y. Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol 2011;85:3649-63. [PMID: 21248044 DOI: 10.1128/JVI.02197-10] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
478 Pellerin M, Lopez-Aguirre Y, Penin F, Dhumeaux D, Pawlotsky JM. Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. J Virol 2004;78:4617-27. [PMID: 15078944 DOI: 10.1128/jvi.78.9.4617-4627.2004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
479 Trapero-Marugán M, Mendoza J, Chaparro M, González-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 2011; 17(4): 493-498 [PMID: 21274379 DOI: 10.3748/wjg.v17.i4.493] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
480 Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009; 15(3): 328-333 [PMID: 19140232 DOI: 10.3748/wjg.15.328] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
481 Scott J, Holte S, Urban T, Burgess C, Coppel E, Wang C, Corey L, McHutchison J, Goldstein D. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J Infect Dis 2011;204:419-25. [PMID: 21742841 DOI: 10.1093/infdis/jir264] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
482 Franzen PL, Buysse DJ, Rabinovitz M, Pollock BG, Lotrich FE. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res. 2010;177:240-245. [PMID: 20381876 DOI: 10.1016/j.psychres.2009.02.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
483 Alsaleh K, Delavalle PY, Pillez A, Duverlie G, Descamps V, Rouillé Y, Dubuisson J, Wychowski C. Identification of basic amino acids at the N-terminal end of the core protein that are crucial for hepatitis C virus infectivity. J Virol 2010;84:12515-28. [PMID: 20943968 DOI: 10.1128/JVI.01393-10] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
484 Callefi LA, Villela-Nogueira CA, de Barros Tenore S, Carnaúba-Júnior D, Coelho HSM, Pinto PTA, Nabuco LC, Pessoa MG, Ferraz MLCG, Ferreira PRA, de Lourdes Candolo Martinelli A, Chachá SGF, de Souza Paiva Ferreira A, de Macedo Bisio AP, Brandão-Mello CE, Álvares-Da-Silva MR, Reuter T, Ivantes CAP, de Mello Perez R, Mendes-Correa MCJ. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics (Sao Paulo) 2017;72:378-85. [PMID: 28658438 DOI: 10.6061/clinics/2017(06)08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
485 Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. [PMID: 32119961 DOI: 10.1016/j.lfs.2020.117477] [Cited by in Crossref: 305] [Cited by in F6Publishing: 290] [Article Influence: 152.5] [Reference Citation Analysis]
486 Kim GW, Jwa SW, Song M, Kim HS, Kim BS, Kim MB, Ko HC. Extensive psoriasis induced by pegylated interferon alfa-2a and ribavirin in the treatment of chronic hepatitis C. Ann Dermatol. 2013;25:479-482. [PMID: 24371397 DOI: 10.5021/ad.2013.25.4.479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
487 Müller B, Kräusslich HG. Antiviral strategies. Handb Exp Pharmacol 2009;:1-24. [PMID: 19048195 DOI: 10.1007/978-3-540-79086-0_1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
488 Johansson S, Talloen W, Tuefferd M, Darling J, Fanning G, Fried MW, Aerssens J. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity. Liver Int 2016;36:344-52. [PMID: 26344576 DOI: 10.1111/liv.12932] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
489 Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014. [PMID: 17039255 DOI: 10.1172/jci2983] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
490 Sato S, Genda T, Hirano K, Tsuzura H, Kanemitsu Y, Narita Y, Kikuchi T, Ijima K, Ichida T. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C. Hepatol Int 2013;7:508-15. [PMID: 21484111 DOI: 10.1007/s12072-011-9273-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
491 Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017;52:385-95. [PMID: 27502287 DOI: 10.1007/s00535-016-1245-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
492 Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PLoS One. 2014;9:e110284. [PMID: 25340799 DOI: 10.1371/journal.pone.0110284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
493 Pawlotsky JM. New antiviral agents for hepatitis C. F1000 Biol Rep. 2012;4:5. [PMID: 22403588 DOI: 10.3410/b4-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
494 Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, Titerence R, Koh C, Cherepanov V, Heller T. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology. 2011;140:830-839. [PMID: 20854821 DOI: 10.1053/j.gastro.2010.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
495 Southern WN, Drainoni ML, Smith BD, Koppelman E, McKee MD, Christiansen CL, Gifford AL, Weinbaum CM, Litwin AH. Physician nonadherence with a hepatitis C screening program. Qual Manag Health Care 2014;23:1-9. [PMID: 24368717 DOI: 10.1097/QMH.0000000000000007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
496 Li K, Frankowski KJ, Belon CA, Neuenswander B, Ndjomou J, Hanson AM, Shanahan MA, Schoenen FJ, Blagg BS, Aubé J, Frick DN. Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline. J Med Chem 2012;55:3319-30. [PMID: 22409723 DOI: 10.1021/jm300021v] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 5.7] [Reference Citation Analysis]
497 Witthoeft T, Fuchs M, Ludwig D. Recent IV-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: An open-label pilot study. World J Gastroenterol 2007; 13(4): 579-584 [PMID: 17278224 DOI: 10.3748/wjg.v13.i4.579] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
498 Ansar M, Ashfaq UA, Shahid I, Sarwar MT, Javed T, Rehman S, Hassan S, Riazuddin S. Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA. Virol J. 2011;8:203. [PMID: 21535893 DOI: 10.1186/1743-422x-8-203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
499 Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z. Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 2012;9:123. [PMID: 22713131 DOI: 10.1186/1743-422X-9-123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
500 Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, Chung TL, Wood BJ, Haagmans BL. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. AIDS. 2011;25:1179-1187. [PMID: 21593619 DOI: 10.1097/qad.0b013e3283471d53] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
501 Al-Qahtani A, Al-Anazi M, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, Al-Ashgar HI, Khan MQ, Albenmousa A, Khalaf N, Viswan N, Al-Ahdal MN. Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection. J Immunol Res 2015;2015:768470. [PMID: 25811035 DOI: 10.1155/2015/768470] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
502 Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014. [PMID: 17039255 DOI: 10.1172/jci29832] [Cited by in Crossref: 110] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
503 Hiramine S, Sugiyama M, Furusyo N, Uto H, Ido A, Tsubouchi H, Watanabe H, Ueno Y, Korenaga M, Murata K, Masaki N, Hayashi J, Thomas DL, Mizokami M. A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. J Gastroenterol 2015;50:1069-77. [PMID: 25735432 DOI: 10.1007/s00535-015-1056-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
504 Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol 2004;15:313-26. [PMID: 18159509 DOI: 10.1155/2004/326964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
505 Yang N, Sun Q, Xu Z, Wang X, Zhao X, Cao Y, Chen L, Fan G. LC-ESI-MS/MS analysis and pharmacokinetics of GP205, an innovative potent macrocyclic inhibitor of hepatitis C virus NS3/4A protease in rats. Molecules 2015;20:4319-36. [PMID: 25756650 DOI: 10.3390/molecules20034319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
506 Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, Owens DK. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans. J Viral Hepat 2015;22:489-95. [PMID: 25417805 DOI: 10.1111/jvh.12344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
507 Gupta R, Ramakrishna C, Lakhtakia S, Tandan M, Banerjee R, Reddy DN. Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. World J Gastroenterol 2006; 12(34): 5554-5556 [PMID: 17006999 DOI: 10.3748/wjg.v12.i34.5554] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
508 Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N. Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial. Dig Dis Sci. 2008;53:2238-2245. [PMID: 18080763 DOI: 10.1007/s10620-007-0129-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
509 Brodsky LI, Wahed AS, Li J, Tavis JE, Tsukahara T, Taylor MW. A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. PLoS One 2007;2:e584. [PMID: 17589564 DOI: 10.1371/journal.pone.0000584] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
510 Weiss JJ, Morgello S. Psychiatric management of HIV/HCV-coinfected patients beginning treatment for hepatitis C virus infection: survey of provider practices. Gen Hosp Psychiatry 2009;31:531-7. [PMID: 19892211 DOI: 10.1016/j.genhosppsych.2009.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
511 Wong VK, Cheong-Lee C, Ford JAE, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy. World J Gastroenterol 2005; 11(34): 5392-5393 [PMID: 16149154 DOI: 10.3748/wjg.v11.i34.5392] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
512 McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology. 2013;57:1325-1332. [PMID: 23315914 DOI: 10.1002/hep.26246] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 8.3] [Reference Citation Analysis]
513 Choi JE, Kwon JH, Kim JH, Hur W, Sung PS, Choi SW, Yoon SK. Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. PLoS One 2015;10:e0119172. [PMID: 25798824 DOI: 10.1371/journal.pone.0119172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
514 Adla M, Downey KK, Ahmad J. Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature. Dig Dis Sci. 2008;53:2810-2812. [PMID: 18320314 DOI: 10.1007/s10620-008-0209-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
515 Plemper RK, Hammond AL. Synergizing vaccinations with therapeutics for measles eradication. Expert Opin Drug Discov 2014;9:201-14. [PMID: 24303998 DOI: 10.1517/17460441.2014.867324] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
516 Peng X, Li Y, Walters KA, Rosenzweig ER, Lederer SL, Aicher LD, Proll S, Katze MG. Computational identification of hepatitis C virus associated microRNA-mRNA regulatory modules in human livers. BMC Genomics 2009;10:373. [PMID: 19671175 DOI: 10.1186/1471-2164-10-373] [Cited by in Crossref: 138] [Cited by in F6Publishing: 123] [Article Influence: 10.6] [Reference Citation Analysis]
517 Wong WWL, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21. [PMID: 25583667 DOI: 10.1503/cmaj.140711] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
518 Erhardt A, Behlen-Wilm U, Adams O, Donner A, Heintges T, Häussinger D. Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. Dig Dis Sci 2003;48:921-5. [PMID: 12772791 DOI: 10.1023/a:1023051613300] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
519 Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, Sane RS. Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 2015;59:25-37. [PMID: 25313217 DOI: 10.1128/AAC.03861-14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
520 Kusano H, Akiba J, Ogasawara S, Sanada S, Yasumoto M, Nakayama M, Ueda K, Ueda K, Kurita T, Todoroki K, Umeno Y, Nakashima O, Yano H. Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One 2013;8:e83195. [PMID: 24349459 DOI: 10.1371/journal.pone.0083195] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
521 Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015; 7(8): 1133-1141 [PMID: 26052402 DOI: 10.4254/wjh.v7.i8.1133] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
522 Martró E, González V, Buckton AJ, Saludes V, Fernández G, Matas L, Planas R, Ausina V. Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5' noncoding and nonstructural 5b genomic regions. J Clin Microbiol 2008;46:192-7. [PMID: 17989191 DOI: 10.1128/JCM.01623-07] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
523 Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, des Jarlais D, Braithwaite RS. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clin Infect Dis 2020;70:2652-62. [PMID: 31400755 DOI: 10.1093/cid/ciz726] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
524 Kimer N, Dahl EK, Gluud LL, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2012;2:e001313. [PMID: 23089208 DOI: 10.1136/bmjopen-2012-001313] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
525 Jiang J, Cun W, Wu X, Shi Q, Tang H, Luo G. Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol 2012;86:7256-67. [PMID: 22532692 DOI: 10.1128/JVI.07222-11] [Cited by in Crossref: 122] [Cited by in F6Publishing: 83] [Article Influence: 12.2] [Reference Citation Analysis]
526 Myers RP, Cooper C, Sherman M, Lalonde R, Witt-Sullivan H, Elkashab M, Harris P, Balshaw R, Usaty C, Marrotta PJ. Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Can J Gastroenterol 2011;25:503-10. [PMID: 21912762 DOI: 10.1155/2011/698780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
527 Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007;20:23-38. [PMID: 17223621 DOI: 10.1128/cmr.00010-06] [Cited by in Crossref: 106] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
528 Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis--an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol. 2009;4:1449-1458. [PMID: 19643927 DOI: 10.2215/cjn.01850309] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
529 Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, Bhan AK, Andersen J, Koziel MJ; ACTG 5071 Study Team. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006;20:345-51. [PMID: 16439867 DOI: 10.1097/01.aids.0000206500.16783.2e] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
530 Gallelli L, Ferraro M, Mauro GF, De Sarro G. Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case. Clin Drug Investig 2005;25:281-4. [PMID: 17523780 DOI: 10.2165/00044011-200525040-00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
531 Sweiss NJ, Zhang W, Franek BS, Kariuki SN, Moller DR, Patterson KC, Bennett P, Girijala LR, Nair V, Baughman RP, Garcia JG, Niewold TB. Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry. PLoS One 2011;6:e29126. [PMID: 22195005 DOI: 10.1371/journal.pone.0029126] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
532 Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z. Hepatitis C treatment: current and future perspectives. Virol J 2010;7:296. [PMID: 21040548 DOI: 10.1186/1743-422X-7-296] [Cited by in Crossref: 65] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
533 Larrubia JR, Moreno-Cubero E, Miquel J, Sanz-de-Villalobos E. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015; 21(12): 3480-3491 [PMID: 25834312 DOI: 10.3748/wjg.v21.i12.3480] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
534 Huang Y, Yang H, Borg BB, Su X, Rhodes SL, Yang K, Tong X, Tang G, Howell CD, Rosen HR. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA. 2007;104:985-990. [PMID: 17215375 DOI: 10.1073/pnas.0609954104] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 5.2] [Reference Citation Analysis]
535 Kanwal F, Hoang T, Chrusciel T, Kramer JR, El-Serag HB, Dominitz JA, Asch SM. Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol 2012;10:1270-1277.e3. [PMID: 22841970 DOI: 10.1016/j.cgh.2012.07.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
536 Lipman MM, Cotler SJ. Antiviral Therapy for Hepatitis C. Curr Treat Options Gastroenterol 2003;6:445-53. [PMID: 14585233 DOI: 10.1007/s11938-003-0046-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
537 Gatselis NK, Zachou K, Saitis A, Samara M, Dalekos GN. Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol 2014; 20(11): 2839-2853 [PMID: 24659876 DOI: 10.3748/wjg.v20.i11.2839] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
538 Nagao Y, Sata M. Analysis of the factors motivating HCV-infected patients to accept interferon therapy. BMC Res Notes 2012;5:470. [PMID: 22932002 DOI: 10.1186/1756-0500-5-470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
539 Chang KO, George DW. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J Virol 2007;81:9633-40. [PMID: 17609266 DOI: 10.1128/JVI.00795-07] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
540 Pol S. Transplantation and viral hepatitis: major progress. Current Opinion in Organ Transplantation 2006;11:579-82. [DOI: 10.1097/mot.0b013e3280105a65] [Reference Citation Analysis]
541 Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001-13014. [PMID: 12438626 DOI: 10.1128/jvi.76.24.13001-13014.2002] [Cited by in Crossref: 898] [Cited by in F6Publishing: 607] [Article Influence: 44.9] [Reference Citation Analysis]
542 Braks RE, Ganne-Carrié N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13(42): 5648-5653 [PMID: 17948941 DOI: 10.3748/wjg.v13.i42.5648] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
543 Chen H, Pei R, Chen X. Different responses of two highly permissive cell lines upon HCV infection. Virol Sin 2013;28:202-8. [PMID: 23818110 DOI: 10.1007/s12250-013-3342-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
544 Jamall IS, Yusuf S, Azhar M, Jamall S. Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3? World J Gastroenterol 2008; 14(43): 6627-6631 [PMID: 19034963 DOI: 10.3748/wjg.14.6627] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
545 Larrubia JR, Benito-Martínez S, Miquel J, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. World J Gastroenterol 2009; 15(41): 5129-5140 [PMID: 19891011 DOI: 10.3748/wjg.15.5129] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
546 Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13(40): 5343-5350 [PMID: 17879404 DOI: 10.3748/wjg.v13.i40.5343] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
547 Jerome KR. The road to new antiviral therapies. Clin Appl Immunol Rev 2005;5:65-76. [PMID: 32362789 DOI: 10.1016/j.cair.2004.10.002] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
548 Abbas Z, Tayyab GN, Qureshi M, Memon MS, Subhan A, Shakir T, Jafri W, Hamid S. Consensus interferon plus ribavirin for hepatitis C genotype 3 patients previously treated with pegylated interferon plus ribavirin. Hepat Mon 2013;13:e14146. [PMID: 24358041 DOI: 10.5812/hepatmon.14146] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
549 Cacopardo B, Nunnari G, Benanti F, Cappellani A, Onorante A, Caltabiano E, Russo R. Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons. Infection 2009;37:210-5. [PMID: 19139808 DOI: 10.1007/s15010-008-8164-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
550 Hazari S, Taylor L, Haque S, Garry RF, Florman S, Luftig R, Regenstein F, Dash S. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J 2007;4:89. [PMID: 17877826 DOI: 10.1186/1743-422X-4-89] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
551 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep 2015;5:11710. [PMID: 26130141 DOI: 10.1038/srep11710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
552 Weiss JJ, Bräu N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009;30:14-27. [PMID: 19416131 DOI: 10.1111/j.1365-2036.2009.04004.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
553 Huang CQ, Wang FX. Progress in research of genotypes of hepatitis C virus. Shijie Huaren Xiaohua Zazhi 2012; 20(35): 3529-3535 [DOI: 10.11569/wcjd.v20.i35.3529] [Reference Citation Analysis]
554 Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011;140:1961-9. [PMID: 21376050 DOI: 10.1053/j.gastro.2011.02.061] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
555 Zhong W, An H, Barawkar D, Hong Z. Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C Virus. Antimicrob Agents Chemother 2003;47:2674-81. [PMID: 12878540 DOI: 10.1128/AAC.47.8.2674-2681.2003] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
556 Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: A review. World J Gastroenterol 2014; 20(10): 2595-2605 [PMID: 24627595 DOI: 10.3748/wjg.v20.i10.2595] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
557 Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, Pollini RA, Garfein RS, Thomas DL, Hagan H; Study to Reduce Intravenous Exposures Project. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005;40 Suppl 5:S304-12. [PMID: 15768339 DOI: 10.1086/427445] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 5.3] [Reference Citation Analysis]
558 Muñoz de Rueda P, Fuentes Rodríguez JM, Quiles Pérez R, Gila Medina A, Martín Álvarez AB, Casado Ruíz J, Ruíz Extremera A, Salmerón J. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. World J Gastroenterol 2017; 23(25): 4538-4547 [PMID: 28740342 DOI: 10.3748/wjg.v23.i25.4538] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
559 Gonzalez HJ, Ho SB, Gross JB, Peine C, McKee D, Smith T; Midwest Hepatitis Study Group. Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C. Dig Dis Sci 2002;47:784-92. [PMID: 11991610 DOI: 10.1023/a:1014792017251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
560 Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol 2011;7:e1001072. [PMID: 21304937 DOI: 10.1371/journal.pcbi.1001072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
561 Méndez-Navarro J, Chirino RA, Corey KE, Gorospe EC, Zheng H, Morán S, Juarez JA, Chung RT, Dehesa-Violante M. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients. Dig Dis Sci 2010;55:2629-35. [PMID: 19960257 DOI: 10.1007/s10620-009-1062-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
562 Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50:434-449. [PMID: 19841158 DOI: 10.1177/0091270009347475] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 6.9] [Reference Citation Analysis]
563 Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206. [PMID: 21449783 DOI: 10.1056/NEJ Moa1010494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
564 Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17(47): 5184-5190 [PMID: 22215943 DOI: 10.3748/wjg.v17.i47.5184] [Cited by in CrossRef: 144] [Cited by in F6Publishing: 141] [Article Influence: 13.1] [Reference Citation Analysis]
565 Michta ML, Hopcraft SE, Narbus CM, Kratovac Z, Israelow B, Sourisseau M, Evans MJ. Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol 2010;84:11696-708. [PMID: 20844048 DOI: 10.1128/JVI.01555-10] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
566 Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020;92:479-490. [PMID: 32052466 DOI: 10.1002/jmv.25707] [Cited by in Crossref: 489] [Cited by in F6Publishing: 430] [Article Influence: 244.5] [Reference Citation Analysis]
567 Woodhouse SD, Smith C, Michelet M, Branza-Nichita N, Hussey M, Dwek RA, Zitzmann N. Iminosugars in combination with interferon and ribavirin permanently eradicate noncytopathic bovine viral diarrhea virus from persistently infected cells. Antimicrob Agents Chemother 2008;52:1820-8. [PMID: 18316522 DOI: 10.1128/AAC.01181-07] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
568 Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med. 2009;15:31-33. [PMID: 19122656 DOI: 10.1038/nm.1902] [Cited by in Crossref: 244] [Cited by in F6Publishing: 228] [Article Influence: 18.8] [Reference Citation Analysis]
569 Wang J, Xin S, Jin X, Cheng Y, Yan T, Qing S, Ding N, Zhao P. Meta-Analysis of Combination Therapy of Chinese Herbs Plus Interferon and Ribavirin in Patients with Chronic Hepatitis C. Med Sci Monit 2016;22:1817-26. [PMID: 27237628 DOI: 10.12659/msm.895647] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
570 Antonelli A, Ferrari SM, Ruffilli I, Fallahi P. Cytokines and HCV-related autoimmune disorders. Immunol Res. 2014;60:311-319. [PMID: 25381483 DOI: 10.1007/s12026-014-8569-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
571 Capra F, De Maria E, Franchini M, Marchiori L, Thalheimer U, Vantini I. Nonresponse to interferon monotherapy in HCV-related chronic hepatitis: results of retreatment and prognostic factors. Dig Dis Sci 2003;48:809-14. [PMID: 12741476 DOI: 10.1023/a:1022813531664] [Reference Citation Analysis]
572 Veldt BJ, Brouwer JT, Adler M, Nevens F, Michielsen P, Delwaide J, Hansen BE, Schalm SW; Benelux Study Group on Treatment of Chronic Hepatitis C. Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. BMC Gastroenterol 2003;3:24. [PMID: 12948399 DOI: 10.1186/1471-230X-3-24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
573 Rafique S, Idrees M, Ilyas M, Hussain A, Ali M, Ali L, Butt S, Afzal S, Ur Rehman I, Saleem S. Positional effect of phosphorylation sites 266 and 267 in the cytoplasmic domain of the E2 protein of hepatitis C virus 3a genotype: interferon resistance analysis via sequence alignment. Virol J 2011;8:204. [PMID: 21545731 DOI: 10.1186/1743-422X-8-204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
574 Howell CD, Gorden A, Ryan KA, Thompson AJ, Ibrahim C, Fried M, Afdhal NH, McHutchison JG, Shianna KV, Goldstein DB. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol. 2012;56:557-563. [PMID: 22027585 DOI: 10.1016/j.jhep.2011.10.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
575 Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int. 2015;28:980-989. [PMID: 25818896 DOI: 10.1111/tri.12568] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
576 Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007;14:371-86. [PMID: 17501757 DOI: 10.1111/j.1365-2893.2006.00816.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
577 Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR; HALT-C Trial Group. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010;51:137-48. [PMID: 20332289 DOI: 10.1176/appi.psy.51.2.137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
578 Ishikawa T, Abe S, Kojima Y, Sano T, Iwanaga A, Seki KI, Honma T, Yoshida T, Yamazaki M, Sakai T, Tasaki K, Suzuki Y. Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin. Exp Ther Med 2015;9:1646-50. [PMID: 26136872 DOI: 10.3892/etm.2015.2340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
579 Shaheen MA, Idrees M. Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol 2015; 7(3): 616-627 [PMID: 25848486 DOI: 10.4254/wjh.v7.i3.616] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
580 Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012;56:4161-7. [PMID: 22615282 DOI: 10.1128/AAC.00324-12] [Cited by in Crossref: 184] [Cited by in F6Publishing: 82] [Article Influence: 18.4] [Reference Citation Analysis]
581 Freedman ND, Curto TM, Morishima C, Seeff Lb, Goodman ZD, Wright EC, Sinha R, Everhart JE, the HALT-C Trial Group. Silymarin use and liver disease progression in the HALT-C trial. Aliment Pharmaol Ther. 2011;33:127-137. [PMID: 21083592 DOI: 10.1111/j.1365-2036.2010.04503.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
582 Wattacheril J, Rose KL, Hill S, Lanciault C, Murray CR, Washington K, Williams B, English W, Spann M, Clements R, Abumrad N, Flynn CR. Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatol Res 2017;47:1469-83. [PMID: 28258704 DOI: 10.1111/hepr.12885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
583 Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J; for the Hepatitis C Study. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009;41:1100-4. [DOI: 10.1038/ng.447] [Cited by in Crossref: 1434] [Cited by in F6Publishing: 1362] [Article Influence: 110.3] [Reference Citation Analysis]
584 Holtzheimer PE, Veitengruber J, Wang CC, Krows M, Thiede H, Wald A, Roy-Byrne P. Utility of the Beck Depression Inventory to screen for and track depression in injection drug users seeking hepatitis C treatment. Gen Hosp Psychiatry 2010;32:426-32. [PMID: 20633748 DOI: 10.1016/j.genhosppsych.2010.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
585 Goyal G, Panag K, Garg R. Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy. Int J Appl Basic Med Res 2016;6:245-8. [PMID: 27857890 DOI: 10.4103/2229-516X.192587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
586 Chiche L, Bataille S, Kaplanski G, Jourde N. The place of immunotherapy in the management of HCV-induced vasculitis: an update. Clin Dev Immunol 2012;2012:315167. [PMID: 22927871 DOI: 10.1155/2012/315167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
587 Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:713-728. [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
588 Ahmad YK, Tawfeek S, Sharaf-Eldin M, Elbatea HE, Kobtan A, El-Kalla F, Badawi R, Abd-Elsalam S. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hosp Pharm 2017;52:294-301. [PMID: 28515509 DOI: 10.1310/hpj5204-294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
589 Yang JF, Kao YH, Dai CY, Huang JF, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int 2010;4:732-40. [PMID: 21286344 DOI: 10.1007/s12072-010-9208-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
590 Liu G, Holmberg SD, Kamili S, Xu F. Racial disparities in the proportion of current, unresolved hepatitis C virus infections in the United States, 2003-2010. Dig Dis Sci 2014;59:1950-7. [PMID: 24573716 DOI: 10.1007/s10620-014-3059-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
591 Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, Holloway MK, Ludmerer SW, McCauley JA, McIntyre CJ. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 2010;54:305-311. [PMID: 19841155 DOI: 10.1128/aac.00677-09] [Cited by in Crossref: 111] [Cited by in F6Publishing: 44] [Article Influence: 8.5] [Reference Citation Analysis]
592 Hou WH, Rossi L, Shan Y, Zheng JY, Lambrecht RW, Bonkovsky HL. Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J Gastroenterol 2009; 15(36): 4499-4510 [PMID: 19777608 DOI: 10.3748/wjg.15.4499] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
593 Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, Bao H, Zennou V, Bourne N, Julander JG. PSI-7851, a pronucleotide of beta-D-2’-deoxy-2’-fluoro-2’-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010;54:3187-3196. [PMID: 20516278 DOI: 10.1128/aac.00399-10] [Cited by in Crossref: 106] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
594 Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol. 2005;79:8217-8229. [PMID: 15956567 DOI: 10.1128/jvi.79.13.8217-8229.2005] [Cited by in Crossref: 222] [Cited by in F6Publishing: 118] [Article Influence: 13.1] [Reference Citation Analysis]
595 Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30:1259-1269. [PMID: 20633102 DOI: 10.1111/j.1478-3231.2010.02283.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 10.2] [Reference Citation Analysis]
596 Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43. [PMID: 28469364 DOI: 10.20524/aog.2017.0136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
597 Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, Mita E, Ito T. Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. J Gastroenterol. 2012;47:334-342. [PMID: 22109353 DOI: 10.1007/s00535-011-0498-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
598 Heck JA, Lam AM, Narayanan N, Frick DN. Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob Agents Chemother 2008;52:1901-11. [PMID: 18391043 DOI: 10.1128/AAC.01496-07] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
599 Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H; Japanese C-Viral Hepatitis Network. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007;56:1747-53. [PMID: 17573387 DOI: 10.1136/gut.2007.120956] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
600 Matsumoto Y, Matsuura T, Aoyagi H, Matsuda M, Hmwe SS, Date T, Watanabe N, Watashi K, Suzuki R, Ichinose S, Wake K, Suzuki T, Miyamura T, Wakita T, Aizaki H. Antiviral activity of glycyrrhizin against hepatitis C virus in vitro. PLoS One 2013;8:e68992. [PMID: 23874843 DOI: 10.1371/journal.pone.0068992] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
601 Loftis JM, Matthews AM, Hauser P. Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. Drugs. 2006;66:155-174. [PMID: 16451091 DOI: 10.2165/00003495-200666020-00003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 3.6] [Reference Citation Analysis]
602 Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study. Balkan Med J 2016;33:18-26. [PMID: 26966614 DOI: 10.5152/balkanmedj.2015.15859] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
603 Alavi M, Grebely J, Matthews GV, Petoumenos K, Yeung B, Day C, Lloyd AR, Van Beek I, Kaldor JM, Hellard M. Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27:957-965. [PMID: 22142332 DOI: 10.1111/j.1440-1746.2011.07035.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
604 Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005;20:754-758. [PMID: 16050887 DOI: 10.1111/j.1525-1497.2005.0161.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 138] [Article Influence: 7.9] [Reference Citation Analysis]
605 Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010;36:165-172. [PMID: 18562341 DOI: 10.1093/schbul/sbn065] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
606 Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017;96:e5321. [PMID: 28072684 DOI: 10.1097/md.0000000000005321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
607 Mathias S, Crosby RD, Bayliss MS, L'Italien G, Sapra S. Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary. Qual Life Res 2014;23:1489-96. [PMID: 24379136 DOI: 10.1007/s11136-013-0609-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
608 Ma X, Yang Y, Tu H, Gao J, Tan YT, Zheng JL, Bray F, Xiang YB. Risk prediction models for hepatocellular carcinoma in different populations. Chin J Cancer Res. 2016;28:150-160. [PMID: 27199512 DOI: 10.21147/j.issn.1000-9604.2016.02.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
609 Campos NG, Salomon JA, Servoss JC, Nunes DP, Samet JH, Freedberg KA, Goldie SJ. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007;120:272-9. [PMID: 17349451 DOI: 10.1016/j.amjmed.2006.06.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
610 Rong X, Xu R, Xiong H, Wang M, Huang K, Chen Q, Li C, Liao Q, Huang J, Xia W, Luo G, Ye X, Zhang M, Fu Y. Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011. Arch Virol 2014;159:3231-7. [PMID: 25085624 DOI: 10.1007/s00705-014-2185-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
611 Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo. J AIDS Clin Res 2015;6:1000410. [PMID: 26052470 DOI: 10.4172/2155-6113.1000410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
612 Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855 [PMID: 26207166 DOI: 10.4254/wjh.v7.i14.1843] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
613 Hupa KL, Jaeckel E, Manns MP. Silymarin for Treatment of Nonalcoholic Steatohepatitis-A New Kid on the Block? Clin Gastroenterol Hepatol 2017;15:1863-5. [PMID: 28804034 DOI: 10.1016/j.cgh.2017.08.005] [Reference Citation Analysis]
614 Sakamaki A, Kamimura K, Fukui N, Watanabe H, Sakai N, Tominaga K, Mizuno K, Takamura M, Kawai H, Sugai T, Yamagiwa S, Someya T, Terai S. A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. BMC Gastroenterol 2019;19:85. [PMID: 31195993 DOI: 10.1186/s12876-019-1013-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
615 Park SH, Park CK, Lee JW, Kim YS, Jeong SH, Kim YS, Kim JH, Hwang SG, Rim KS, Yim HJ, Cheong JY, Cho SW, Lee JS, Park YM, Jang JW, Lee CK, Shon JH, Yang JM, Ju YS. Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut Liver 2012;6:98-106. [PMID: 22375178 DOI: 10.5009/gnl.2012.6.1.98] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
616 Schäfer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007;16:186-201. [PMID: 18188838 DOI: 10.1002/mpr.229] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
617 Saunier B, Triyatni M, Ulianich L, Maruvada P, Yen P, Kohn LD. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol. 2003;77:546-559. [PMID: 12477859 DOI: 10.1128/jvi.77.1.546-559.2003] [Cited by in Crossref: 90] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
618 Herrine SK, Brown RS, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci. 2005;50:719-726. [PMID: 15844708 DOI: 10.1007/s10620-005-2563-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
619 Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, Abe H, Miki D, Imamura M, Takahashi S. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS One. 2011;6:e23856. [PMID: 21886832 DOI: 10.1371/journal.pone.0023856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
620 Vigani AG, Pavan MH, Tozzo R, Gonçales ES, Feltrin A, Fais VC, Lazarini MS, Gonçales NS, Gonçales FL Jr. Comparative study of patients with chronic hepatitis C virus infection due to genotypes 1 and 3 referred for treatment in southeast Brazil. BMC Infect Dis 2008;8:164. [PMID: 19055835 DOI: 10.1186/1471-2334-8-164] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
621 Hajiaghamohammadi A, Samimi R, Miroliaee A, Kazemifar AM, Nazem M. Treatment outcome in chronic hepatitis C infection: a four years survey among Iranian patients. Glob J Health Sci 2014;7:75-81. [PMID: 25948447 DOI: 10.5539/gjhs.v7n3p75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
622 Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, Moriishi K, Matsuura Y. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 2006;25:5015-5025. [PMID: 17024179 DOI: 10.1038/sj.emboj.7601367.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
623 Yan KK, Guirgis M, Dinh T, George J, Dev A, Lee A, Zekry A. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008; 14(21): 3416-3420 [PMID: 18528940 DOI: 10.3748/wjg.14.3416] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
624 Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4:20-26. [PMID: 20485532 DOI: 10.1097/adm.0b013e3181add3de] [Cited by in Crossref: 51] [Cited by in F6Publishing: 23] [Article Influence: 5.7] [Reference Citation Analysis]
625 Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M Jr, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis 2009;200:866-76. [PMID: 19673650 DOI: 10.1086/605475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
626 You BC, Kim YS, Kim Hi, Kim SH, Park SS, Seo YR, Kim SG, Lee SW, Kim HS, Jeong SW, Jang JY, Kim BS. A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. Clin Mol Hepatol 2012;18:272-8. [PMID: 23091807 DOI: 10.3350/cmh.2012.18.3.272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
627 Gordon CE, Uhlig K, Schmid CH, Levey AS, Wong JB. Long-term viral negativity after interferon for chronic hepatitis C virus infection in hemodialysis. Clin J Am Soc Nephrol. 2011;6:2226-2234. [PMID: 21784816 DOI: 10.2215/cjn.00410111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
628 Sauvage FL, Stanke-Labesque F, Gagnieu MC, Jourdil JF, Babany G, Marquet P. Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit 2009;31:374-81. [PMID: 19412142 DOI: 10.1097/FTD.0b013e3181a665e3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
629 Parra-Guillen ZP, Fioravanti J, Medina-Echeverz J, Gomar C, Ardaiz N, Troconiz IF, Berraondo P. Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I. PLoS One 2012;7:e42100. [PMID: 22848716 DOI: 10.1371/journal.pone.0042100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
630 Litwin AH, Kunins HV, Berg KM, Federman AD, Heavner KK, Gourevitch MN, Arnsten JH. Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat. 2007;33:99-105. [PMID: 17379472 DOI: 10.1016/j.jsat.2006.12.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
631 Weatherford T, Chavez D, Brasky KM, Lemon SM, Martin A, Lanford RE. Lack of adaptation of chimeric GB virus B/hepatitis C virus in the marmoset model: possible effects of bottleneck. J Virol 2009;83:8062-75. [PMID: 19474092 DOI: 10.1128/JVI.00032-09] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
632 Cannon NA, Donlin MJ, Mayes LM, Lyra AC, Di Bisceglie AM, Tavis JE. Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. J Viral Hepat 2009;16:595-604. [PMID: 19243495 DOI: 10.1111/j.1365-2893.2009.01109.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
633 Zoller H, Vogel W. Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha. Int J Nanomedicine 2006;1:399-409. [PMID: 17722274 DOI: 10.2147/nano.2006.1.4.399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
634 Witthöft T. Review of consensus interferon in the treatment of chronic hepatitis C. Biologics 2008;2:635-43. [PMID: 19707444 DOI: 10.2147/btt.s1852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
635 Sung H, Chang M, Saab S. Management of Hepatitis C Antiviral Therapy Adverse Effects. Curr Hepat Rep. 2011;10:33-40. [PMID: 21423320 DOI: 10.1007/s11901-010-0078-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
636 Dufner-Beattie J, O'Guin A, O'Guin S, Briley A, Wang B, Balsarotti J, Roth R, Starkey G, Slomczynska U, Noueiry A, Olivo PD, Rice CM. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B. Antimicrob Agents Chemother 2014;58:3399-410. [PMID: 24709254 DOI: 10.1128/AAC.00113-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
637 Yee LJ, Im K, Wahed AS, Bugawan T, Li J, Rhodes SL, Erlich H, Rosen HR, Liang TJ, Yang H; Virahep-C Study. Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Chemother 2009;53:615-21. [PMID: 18852273 DOI: 10.1128/AAC.00947-08] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
638 Vukobrat-Bijedic Z, Husic-Selimovic A, Mehinovic L, Mehmedovic A, Junuzovic D, Bjelogrlic I, Sofic A, Djurovic A. Analysis of effect of antiviral therapy on regression of liver fibrosis in patient with HCV infection. Mater Sociomed. 2014;26:172-176. [PMID: 25126010 DOI: 10.5455/msm.2014.26.172-176] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
639 Yuan H, Adams-Huet B, Petersen T, Attar N, Lee WM, Jain MK. A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. J Med Virol. 2012;84:1913-1919. [PMID: 23080496 DOI: 10.1002/jmv.23407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
640 El-Fakharany EM, El-Baky NA, Linjawi MH, Aljaddawi AA, Saleem TH, Nassar AY, Osman A, Redwan EM. Influence of camel milk on the hepatitis C virus burden of infected patients. Exp Ther Med 2017;13:1313-20. [PMID: 28413471 DOI: 10.3892/etm.2017.4159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
641 Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima A, Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. Gut Liver 2016;10:617-23. [PMID: 26601828 DOI: 10.5009/gnl15193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
642 Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
643 Reluga TC, Dahari H, Perelson AS. ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS. SIAM J Appl Math 2009;69:999-1023. [PMID: 19183708 DOI: 10.1137/080714579] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
644 Forde KA, Law C, O’Flynn R, Kaplan DE. Do statins reduce hepatitis C RNA titers during routine clinical use? World J Gastroenterol 2009; 15(40): 5020-5027 [PMID: 19859994 DOI: 10.3748/wjg.15.5020] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
645 Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53:1100-1108. [PMID: 21480316 DOI: 10.1002/hep.24169] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
646 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
647 Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012;56:313-319. [PMID: 21703177 DOI: 10.1016/j.jhep.2011.04.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
648 Nguyen DL, Morgan TR. Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection. Clin Liver Dis (Hoboken) 2012;1:54-7. [PMID: 25688295 DOI: 10.1002/cld.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
649 Yu Y, Jing JF, Tong XK, He PL, Li YC, Hu YH, Tang W, Zuo JP. Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease. Acta Pharmacol Sin 2014;35:1074-81. [PMID: 25066323 DOI: 10.1038/aps.2014.55] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
650 Sylvestre D. Hepatitis C for addiction professionals. Addict Sci Clin Pract 2007;4:34-41. [PMID: 18292708 DOI: 10.1151/ascp074134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
651 Inoue Y, Homma M, Matsuzaki Y, Shibata M, Matsumura T, Ito T, Mitamura K, Tanaka N, Kohda Y. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother 2004;48:3813-6. [PMID: 15388439 DOI: 10.1128/AAC.48.10.3813-3816.2004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
652 Bailly F, Ahmed SN, Pradat P, Trepo C. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-95. [PMID: 20377334 DOI: 10.1586/eri.10.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
653 Dev A, Patel K, McHutchison JG. New therapies for chronic hepatitis C virus infection. Curr Gastroenterol Rep. 2004;6:77-86. [PMID: 14720458 DOI: 10.1007/s11894-004-0030-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
654 Shafran SD. The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol 2015;29:46-8. [PMID: 25706574 DOI: 10.1155/2015/216395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
655 Strader DB, Seeff LB. A brief history of the treatment of viral hepatitis C. Clin Liver Dis. 2012;1:6-11. [PMID: 31186837 DOI: 10.1002/cld.1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
656 Clark BT, Garcia-Tsao G, Fraenkel L. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection. Patient Prefer Adherence 2012;6:285-95. [PMID: 22536063 DOI: 10.2147/PPA.S30111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
657 Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450-458.e1. [PMID: 21036173 DOI: 10.1053/j.gastro.2010.10.047] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 7.9] [Reference Citation Analysis]
658 Ke H, Yoo D. The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Vet Microbiol 2017;209:75-89. [PMID: 28341332 DOI: 10.1016/j.vetmic.2017.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
659 Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, Moriishi K, Matsuura Y. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 2006;25:5015-5025. [PMID: 17024179 DOI: 10.1038/sj.emboj.7601367] [Cited by in Crossref: 184] [Cited by in F6Publishing: 173] [Article Influence: 11.5] [Reference Citation Analysis]
660 El Awady MK, Azzazy HM, Fahmy AM, Shawky SM, Badreldin NG, Yossef SS, Omran MH, Zekri ARN, Goueli SA. Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy. World J Gastroenterol 2009; 15(12): 1480-1486 [PMID: 19322922 DOI: 10.3748/wjg.15.1480] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
661 Suzuki H, Takagi H, Sohara N, Kanda D, Kakizaki S, Sato K, Mori M. Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: A randomized controlled clinical trial. World J Gastroenterol 2006; 12(8): 1265-1269 [PMID: 16534882 DOI: 10.3748/wjg.v12.i8.1265] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
662 Oh IS, Won JW, Kim HJ, Lee HW. Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. Korean J Intern Med 2017;32:1010-7. [PMID: 28797159 DOI: 10.3904/kjim.2016.405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]</